var title_f21_14_21728="TEE transverse aorta and aortic arch";
var content_f21_14_21728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse aorta (aortic arch) on transesophageal echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) Horizontal (0&deg;) imaging plane demonstrates the transverse aorta (TrAo).",
"    <br/>",
"    (Panel B) With gentle flexion and anterior rotation the ascending aorta (AAo) may be seen.",
"    <br/>",
"    (Panel C) Color flow Doppler imaging demonstrates normal flow in the aorta (red-orange) with lower velocity superior vena caval (SVC) flow in the opposite direction (blue).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Warren Manning, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21728=[""].join("\n");
var outline_f21_14_21728=null;
var title_f21_14_21729="ARF fistulotomy";
var content_f21_14_21729=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Schematic depiction of a fistulotomy and marsupialization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This diagram shows the probe extending through the primary opening of the anal fistula and the insertion of the probe. The internal opening is excised and the fistulous tract is marsupialized.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21729=[""].join("\n");
var outline_f21_14_21729=null;
var title_f21_14_21730="Fibroid embolization 5b";
var content_f21_14_21730=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sagittal view of pelvic MR",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 497px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A Sagittal view of pelvic MR with gadolinium one year after uterine fibroid embolization shows almost complete resolution of the fibroid with a small residual avascular area (arrow) in the myometrium. The uterus appears normal in size and shape. She had a successful full-term pregnancy and healthy baby following uterine fibroid embolization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21730=[""].join("\n");
var outline_f21_14_21730=null;
var title_f21_14_21731="Urothelial dysplasia C";
var content_f21_14_21731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urothelial dysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21731=[""].join("\n");
var outline_f21_14_21731=null;
var title_f21_14_21732="Betaxolol (ophthalmic): Patient drug information";
var content_f21_14_21732=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Betaxolol (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/53/4950?source=see_link\">",
"     see \"Betaxolol (ophthalmic): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7995904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Betoptic S&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7995905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Betoptic&reg; S;",
"     </li>",
"     <li>",
"      Sandoz-Betaxolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high eye pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701621",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to betaxolol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very weak heart or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11128 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-55CBC6BF0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21732=[""].join("\n");
var outline_f21_14_21732=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995904\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995905\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030229\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030228\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030233\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030234\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030236\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030231\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030232\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030237\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030238\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/53/4950?source=related_link\">",
"      Betaxolol (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/24/37255?source=related_link\">",
"      Betaxolol (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/33/18965?source=related_link\">",
"      Betaxolol (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_14_21733="Mexiletine: Pediatric drug information";
var content_f21_14_21733=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mexiletine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"    see \"Mexiletine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/14/31972?source=see_link\">",
"    see \"Mexiletine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F196174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Novo-Mexiletine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiarrhythmic Agent, Class I-B",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"      see \"Mexiletine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Range: 1.4-5 mg/kg/dose (mean: 3.3 mg/kg/dose) given every 8 hours; start with lower initial dose and increase according to effects and serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Initial: 200 mg every 8 hours (may load with 400 mg if necessary); adjust dose every 2-3 days; usual dose: 200-300 mg every 8 hours; some patients may respond to the same daily dose divided every 12 hours; maximum dose: 1.2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Children and Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% to 75% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic disease:",
"     </b>",
"     Children and Adults: Administer 25% to 30% of normal dose; patients with severe liver disease may require even lower doses, monitor closely",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 150 mg, 200 mg, 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F196137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food, milk, or antacids to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of serious ventricular arrhythmias; suppression of premature ventricular contractions; diabetic neuropathy",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F196224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, chest pain, palpitation, premature ventricular contractions, proarrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, depression, dizziness, headache, incoordination, insomnia, lightheadedness, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, GI distress, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgias, ataxia, numbness of fingers or toes, paresthesia, trembling, tremor, unsteady gait, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, alopecia, AV block, cardiogenic shock, CHF, dysphagia, exfoliative dermatitis, hallucinations, hepatic necrosis, hepatitis, hypotension, impotence, leukopenia, myelofibrosis, pancreatitis (rare), psychosis, pulmonary fibrosis, seizure, sinus arrest, SLE syndrome, Stevens-Johnson syndrome, syncope, thrombocytopenia, torsade de pointes, upper GI bleeding, urinary retention, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mexiletine or any component; cardiogenic shock; second or third degree heart block (except in patients with a functioning artificial pacemaker)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with seizure disorders, severe heart failure, hypotension, hepatic impairment; avoid dietary regimens or concomitant drug therapy that markedly change urine pH",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, nonlife-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide. An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Worsening of arrhythmia (including ventricular tachycardia or ventricular fibrillation) may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Blood dyscrasias (including leukopenia, agranulocytosis, and thrombocytopenia) have been reported.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F196212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F196146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Mexiletine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Mexiletine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Mexiletine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Mexiletine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sertraline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Mexiletine may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may decrease the rate, but not the extent of oral absorption; diets which affect urine pH can increase or decrease excretion of mexiletine; avoid dietary changes that alter urine pH",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F196148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14206276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. A few case reports have demonstrated safe use of mexiletine in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver enzymes, CBC, ECG, heart rate, serum concentrations",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1054052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic range: 0.5-2 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Potentially toxic: &gt;2 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Class IB antiarrhythmic; structurally related to lidocaine; may cause increase in systemic vascular resistance and decrease in cardiac output; no significant negative inotropic effect",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Oral: 30-120 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 5-7 L/kg; found in breast milk in similar concentrations as plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein-binding: 50% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver (some minor active metabolites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 88%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, adults: 10-14 hours; increase in half-life with hepatic or heart failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 10% to 15% excreted unchanged in urine; urinary acidification increases excretion",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/14/31972?source=see_link\">",
"      see \"Mexiletine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit caffeine; may cause dizziness; notify physician if persistent abdominal pain, nausea, vomiting, yellowing of the eyes or skin, pale stools, dark urine, fever, sore throat, bleeding, or bruising occurs",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. form under investigation",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11429744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 10 mg/mL oral suspension may be with made with capsules and either distilled water or sorbitol USP. Empty the contents of eight 150 mg capsules in a mortar and reduce to a fine powder if necessary. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a graduated cylinder, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label \"shake well\". Sorbitol suspension is stable in plastic prescription bottles for 2 weeks at room temperature and 4 weeks refrigerated; distilled water suspension is stable in plastic prescription bottles for 7 weeks at room temperature and 13 weeks refrigerated. Extended storage under refrigeration is recommended to minimize microbial contamination.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Morosco RS, and Hipple TF, \"Stability of Mexiletine in Two Extemporaneous Liquid Formulations Stored Under Refrigeration and at Room Temperature,\"",
"     <i>",
"      J Am Pharm Assoc (Wash)",
"     </i>",
"     , 2000, 40(2):257-9.",
"     <span class=\"pubmed-id\">",
"      10730027",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Moak JP, Smith RT, and Garson A Jr, &ldquo;Mexiletine: An Effective Antiarrhythmic Drug for Treatment of Ventricular Arrhythmias in Congenital Heart Disease,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1987, 10(4):824-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/14/21733/abstract-text/3655149/pubmed\" id=\"3655149\" target=\"_blank\">",
"        3655149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12608 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21733=[""].join("\n");
var outline_f21_14_21733=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709085\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196174\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054050\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054044\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196151\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196137\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054054\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054053\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196224\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054059\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054043\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054042\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196212\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196146\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054062\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196148\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14206276\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054049\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054052\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054041\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054057\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054058\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054048\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054060\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11429744\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12608\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12608|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=related_link\">",
"      Mexiletine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/14/31972?source=related_link\">",
"      Mexiletine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_14_21734="Apomorphine: Drug information";
var content_f21_14_21734=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Apomorphine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/31/31220?source=see_link\">",
"    see \"Apomorphine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Apokyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F136203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Parkinson's Agent, Dopamine Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F136187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Begin antiemetic therapy 3 days prior to initiation and continue for 2 months before reassessing need.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parkinson's disease, &ldquo;off&rdquo; episode:",
"     </b>",
"     SubQ: Initial test dose 2 mg,",
"     <b>",
"      medical supervision required; see &ldquo;Note&rdquo;",
"     </b>",
"     . Subsequent dosing is based on both tolerance and response to initial test dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If patient tolerates test dose and responds: Starting dose: 2 mg as needed; may increase dose in 1 mg increments every few days; maximum dose: 6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If patient tolerates but does not respond to 2 mg test dose: Second test dose: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If patient tolerates and responds to 4 mg test dose: Starting dose: 3 mg, as needed for &ldquo;off&rdquo; episodes; may increase dose in 1 mg increments every few days; maximum dose 6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If patient does not tolerate 4 mg test dose: Third test dose: 3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If patient tolerates 3 mg test dose: Starting dose: 2 mg as needed for &ldquo;off&rdquo; episodes; may increase dose in 1 mg increments to a maximum of 3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      If therapy is interrupted for &gt;1 week, restart at 2 mg and gradually titrate dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Medical supervision is required for all test doses with standing and supine blood pressure monitoring predose and 20-, 40-, and 60 minutes postdose. If subsequent test doses are required, wait &gt;2 hours before another test dose is given; next test dose should be timed with another &ldquo;off&rdquo; episode. If a single dose is ineffective for a particular &ldquo;off&rdquo; episode, then a second dose should not be given. The average dosing frequency was 3 times/day in the development program with limited experience in dosing &gt;5 times/day and with total daily doses &gt;20 mg. Apomorphine is intended to treat the &ldquo;off&rdquo; episodes associated with levodopa therapy of Parkinson's disease and has not been studied in levodopa-naive Parkinson's patients.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F136188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F136189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: Reduce test dose and starting dose: 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: Has not been studied",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F136190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: Use caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: Has not been studied",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Apokyn&reg;: 10 mg/mL (3 mL) [contains benzyl alcohol, sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11447031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apokyn&reg; is only available through a select group of specialty pharmacies and cannot be obtained through a retail pharmacy. Apokyn&reg;  may be obtained from the following specialty pharmacies: Accredo Nova Factor or PharmaCare. To obtain the medication, contact the APOKYN Call Center at 1-877-7APOKYN (1-877-727-6596).",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F136167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Initiate antiemetic 3 days before test dose of apomorphine and continue for 2 months (if patient to be treated) before reassessment. Administer in abdomen, upper arm, or upper leg; change site with each injection. 3 mL cartridges are used with a manual, reusable, multidose injector pen. Injector pen can deliver doses up to 1 mL in 0.02 mL increments. Do not give intravenously; thrombus formation or pulmonary embolism may occur.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F136166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypomobility, &ldquo;off&rdquo; episodes with Parkinson's disease",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F136199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of erectile dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F136201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain/pressure or angina (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness or somnolence (35%), dizziness or orthostatic hypotension (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea and/or vomiting (30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Falls (30%), dyskinesias (24% to 35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Yawning (40%), rhinorrhea (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (10%), vasodilation (3%), hypotension (2%), syncope (2%), CHF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Hallucinations or confusion (10%), anxiety, depression, fatigue, headache, insomnia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bruising",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgias, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Aggression, agitation, angina, cardiac arrest, confusion, focal panniculitis, libido increased, MI, paranoia, priapism, psychosexual stimulation, psychosis (acute), skin nodules, sudden death",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reported with dopamine agonists: Impulsive/compulsive behaviors (eg, pathological gambling, hypersexuality, binge eating)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F136170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to apomorphine or any component of the formulation;",
"     <b>",
"      concomitant use with 5-HT",
"      <sub>",
"       3",
"      </sub>",
"     </b>",
"     <b>",
"      antagonists",
"     </b>",
"     ; intravenous administration",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F136155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hallucinations/psychosis: May cause hallucinations or psychotic-like behavior or thoughts (eg. paranoia, delusions, confusion, aggression, agitation, delirium); avoid in patients with major psychotic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impulse control disorders: Dopamine agonists used for Parkinson&rsquo;s disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Melanoma: Risk for melanoma development is increased in Parkinson&rsquo;s disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; Parkinson's disease patients appear to have an impaired capacity to respond to a postural challenge. Use with caution in patients at risk of hypotension (such as those receiving antihypertensive drugs) or where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). Parkinson's patients being treated with dopaminergic agonists ordinarily require careful monitoring for signs and symptoms of postural hypotension, especially during dose escalation, and should be informed of this risk. Orthostasis peaks 20 minutes after dosing and lasts at least 90 minutes. If patient develops clinically-significant orthostatic hypotension with test dose, then apomorphine should not be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pleural/retroperitoneal fibrosis: Ergot-derived dopamine agonists have also been associated with fibrotic complications (eg, retroperitoneal fibrosis, pleural thickening, and pulmonary infiltrates); monitor closely for signs and symptoms of fibrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal changes: Pathologic degenerative changes were observed in the retinas of albino rats during studies with this agent, but were not observed in the retinas of albino mice or in other species. The significance of these data for humans remains uncertain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Somnolence: Patients have reported falling asleep while engaging in activities of daily living; this has been reported to occur without significant warning signs. Monitor for daytime somnolence or pre-existing sleep disorder; caution with concomitant sedating medication; discontinue if significant daytime sleepiness or episodes of falling asleep occur. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Use with caution in patients receiving other CNS depressants or psychoactive agents. Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; hypotension may cause coronary ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular disease: Use with caution in patients with cerebrovascular disease; hypotension may cause cerebral ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dyskinesias: Use with caution in patients with pre-existing dyskinesias; may be exacerbated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients at risk for torsade de pointes: Use with caution in patients with risk factors for torsade de pointes (hypokalemia, hypomagnesemia, bradycardia, concurrent use of drugs that prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     , or genetic predisposition).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic pretreatment:",
"     <b>",
"      Pretreatment with antiemetic is necessary;",
"     </b>",
"     avoid pretreatment with antidopaminergic and antiserotonin antiemetic agents (antiemetic experience is greatest with trimethobenzamide).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metabisulfite: Contains metabisulfite which may cause allergic reactions in some individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse: Rare cases of abuse have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration: Do not give intravenously; thrombus formation or pulmonary embolism may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome on abrupt withdrawal or significant dosage reduction after long-term use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F136196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of COMT, CYP1A2 (minor), CYP2C19 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C19 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiemetics (5HT3 Antagonists): May enhance the hypotensive effect of Apomorphine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Atypical): May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Typical): Anti-Parkinson's Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F136181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Ethanol: Caution with ethanol consumption; may increase risk of hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted; use only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F136193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Apokyn Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (3 mL): $1194.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F136163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Each test dose: Supine and standing blood pressure predose and 20, 40, and 60 minutes postdose; drowsiness",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F136173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Go (AT, CZ, DE, DK, ES, GR, HK, HN, IE, IL, NL, NO, PT, SE, TR, TW);",
"     </li>",
"     <li>",
"      APO-go (PL);",
"     </li>",
"     <li>",
"      Apofin (IT);",
"     </li>",
"     <li>",
"      Apomine (NZ);",
"     </li>",
"     <li>",
"      Apomine PFS (AU);",
"     </li>",
"     <li>",
"      Britaject (PL);",
"     </li>",
"     <li>",
"      Ixense (JP);",
"     </li>",
"     <li>",
"      NOC (CN);",
"     </li>",
"     <li>",
"      Stillman (PY);",
"     </li>",
"     <li>",
"      Taluvian (FR);",
"     </li>",
"     <li>",
"      Uprima (AE, BH, BR, CY, EE, EG, IQ, IR, JO, KP, KW, LB, LY, OM, PL, QA, SA, SY, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F136154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates postsynaptic D2-type receptors within the caudate putamen in the brain.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F136169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: SubQ: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Mean: 218 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not established; potential routes of metabolism include sulfation, N-demethylation, glucuronidation, and oxidation; catechol-O methyltransferase and nonenzymatic oxidation. CYP isoenzymes do not appear to play a significant role.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 40 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Improved motor scores: 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine 93% (as metabolites); feces 16%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Factor SA, &ldquo;Current Status of Symptomatic Medical Therapy in Parkinson&rsquo;s Disease,&rdquo;",
"      <i>",
"       Neurotherapeutics",
"      </i>",
"      , 2008, 5(2):164-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/14/21734/abstract-text/18394561/pubmed\" id=\"18394561\" target=\"_blank\">",
"        18394561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina JA, S&agrave;inz-Artiga MJ, Fraile A, et al, &ldquo;Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,&rdquo;",
"      <i>",
"       Mov Disord",
"      </i>",
"      , 2000, 15(5):869-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/14/21734/abstract-text/11009192/pubmed\" id=\"11009192\" target=\"_blank\">",
"        11009192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weintraub D, Siderowf AD, Potenza MN, et al, &ldquo;Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 2006, 63(7):969-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/14/21734/abstract-text/16831966/pubmed\" id=\"16831966\" target=\"_blank\">",
"        16831966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9374 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21734=[""].join("\n");
var outline_f21_14_21734=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136184\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136203\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136187\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136188\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136189\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136190\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136165\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136152\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11447031\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136167\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136166\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136199\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136201\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136170\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136155\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136196\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136159\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136181\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136161\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136171\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136193\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570476\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136163\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136173\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136154\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136169\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9374\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9374|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/31/31220?source=related_link\">",
"      Apomorphine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_14_21735="Endorectal endoscopic ultrasound in the evaluation of fecal incontinence";
var content_f21_14_21735=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endorectal endoscopic ultrasound in the evaluation of fecal incontinence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/14/21735/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21735/contributors\">",
"     David A Schwartz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21735/contributors\">",
"     Maurits J Wiersema, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/14/21735/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21735/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/14/21735/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21735/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/14/21735/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecal incontinence is one of the most devastating of all physical disabilities since it affects self-confidence and personal image, and can lead to social isolation. Previously, the evaluation of fecal incontinence was largely limited to anal manometry, electromyography (EMG), and studies of pudendal nerve latency. Although helpful, these tests provide no direct structural evidence of sphincter injury. Imaging of the anal sphincter is helpful in all patients with fecal incontinence to assess the structure and integrity of the sphincters. Newer imaging modalities, such as endorectal ultrasound (which can be performed with a transrectal ultrasound probe or with endoscopic ultrasonography) and MRI, have added to the diagnostic tools available to clinicians for the evaluation of fecal incontinence. Ultrasound imaging of the anal sphincter provides complementary structural information to the functional information that can be obtained with manometry and should be performed in combination with this test. This topic review will focus on the use of endorectal endoscopic ultrasound (EUS) in the evaluation of fecal incontinence. An overview of fecal incontinence is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=see_link\">",
"     \"Fecal incontinence in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL ULTRASOUND APPEARANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal ultrasound appearance of the anorectum has been well delineated in several studies performed on normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. Two discrete rings of tissue can be seen when using a radial scanning echoendoscope to examine the anorectum (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56203 \" href=\"UTD.htm?27/54/28516\">",
"     image 1",
"    </a>",
"    ). The inner hypoechoic ring of tissue represents the internal anal sphincter (IAS), which is formed by the thickened continuation of the circular smooth muscle of the rectum. The outer hyperechoic ring of tissue represents the longitudinal muscle and the external anal sphincter (EAS), which is formed by the downward extension of the skeletal muscle of the puborectalis. The normal IAS is between 2 to 3 mm thick [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/2,5\">",
"     2,5",
"    </a>",
"    ] and the normal EAS is between 7 to 9 mm thick [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/2,6,9\">",
"     2,6,9",
"    </a>",
"    ]. The IAS becomes thicker and more hyperechoic with age, probably reflecting collagen replacement of the IAS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/5\">",
"     5",
"    </a>",
"    ]. Conversely, the EAS tends to become thinner with age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/6\">",
"     6",
"    </a>",
"    ]. The perineal body is not clearly defined with ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The anal canal length varies from 25 mm for women to 33 mm for men [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a different configuration of the anterior part of the EAS in men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/12\">",
"     12",
"    </a>",
"    ]. The anterior part of this sphincter seems to be shorter and slopes downward in women. This can make demonstrating a complete 360 degree ring of the EAS in one plane difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/9\">",
"     9",
"    </a>",
"    ]. It is essential to recognize this variation so that one does not incorrectly diagnose an anterior sphincter defect where one does not exist. The anococcygeal ligament appears as a hypoechoic triangular structure posteriorly and can be confused as a sphincter defect in this location.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ENDORECTAL ULTRASOUND AND EMG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before the development of endosonography, electromyography (EMG) was used to assess the integrity of the EAS. However, EMG studies were poorly tolerated since they required insertion of needles directly into the muscle. The first reports on the use of ultrasound to study the anal sphincter came from St. Mark's Hospital in the late 1980s and early 1990s. A study comparing electromyography (EMG) with ultrasound in 15 patients with fecal incontinence showed that endosonography could accurately identify EAS defects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/13\">",
"     13",
"    </a>",
"    ]. The correlation between EMG and ultrasound was 0.96. In addition, ultrasound was better tolerated. A follow-up study of 45 patients found that ultrasound agreed with EMG assessment of the external sphincter in all patients studied [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/14\">",
"     14",
"    </a>",
"    ]. In a separate study, the same group used endosonography to direct EMG needle placement into the sphincter defect seen on ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/15\">",
"     15",
"    </a>",
"    ]. In all of the patients where EMG was technically successful, EMG showed no evidence of electrical activity, thus confirming the accuracy of endosonography. It is largely because of these studies that endosonography has replaced EMG as the investigation of choice to identify sphincter defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TEST CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have reported the utility of endosonography in identifying sphincter injuries in patients with fecal incontinence (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69420 \" href=\"UTD.htm?22/43/23219\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/16-33\">",
"     16-33",
"    </a>",
"    ]. Several of these reports have compared the ultrasound findings to the results of surgery (sphincteroplasty). Sensitivity exceeded 90 percent in most reports; specificity is hard to determine from these studies since patients in whom a tear was not strongly suspected may not have been operated on. However, false positive results have been described. The following illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study compared ultrasound and manometric findings in 20 asymptomatic nulliparous women, 20 asymptomatic parous women, and 31 women with incontinence who underwent sphincteroplasty [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/34\">",
"       34",
"      </a>",
"      ]. Endosonography correctly identified all of the sphincter injuries in the women with incontinence.",
"     </li>",
"     <li>",
"      In a similar report, endorectal EUS was performed prior to surgery in 28 patients with fecal incontinence [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/35\">",
"       35",
"      </a>",
"      ]. EUS correctly identified all 25 of the IAS defects and all 10 EAS defects. However, it incorrectly diagnosed an EAS defect in three patients, resulting in an overall accuracy for EUS of 89 percent.",
"     </li>",
"     <li>",
"      In the largest study to date, the ultrasound appearance was prospectively compared with the operative findings in 44 patients who underwent pelvic floor repair [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/36\">",
"       36",
"      </a>",
"      ]. Endorectal ultrasound was 100 percent sensitive in detecting either IAS or EAS defects. One IAS tear seen on endosonography was not confirmed at surgery.",
"     </li>",
"     <li>",
"      The group from St. Mark's published a study prospectively comparing the results of endosonography with manometry and EMG in 12 patients who were scheduled to undergo sphincter repair [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/37\">",
"       37",
"      </a>",
"      ]. Nine of the 12 patients were found to have an EAS defect at surgery. Histology was used as the gold standard. Ultrasound was superior to the other modalities with an accuracy of 100 percent for detecting a sphincter injury compared to an accuracy of 75 percent for manometry, 75 percent for EMG, and 50 percent for clinical assessment. In addition, there was an association between an EAS defect and a decreased maximum squeeze pressure on manometry.",
"     </li>",
"     <li>",
"      Other studies have found a similar association between decreased maximal squeeze pressure and decreased EAS thickness or an EAS defect [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/10,38\">",
"       10,38",
"      </a>",
"      ]. In contrast, a similar relationship between the resting pressure in the anal canal and IAS thickness has not been documented [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/8,38\">",
"       8,38",
"      </a>",
"      ]. The IAS increases in size with age [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/6,39\">",
"       6,39",
"      </a>",
"      ]. Thus, a thicker IAS may actually represent replacement of the smooth muscle of the IAS by connective tissue and not more muscle mass.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ULTRASOUND AND MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have compared the accuracy of transrectal ultrasound and MRI for detecting sphincter injuries. The results have been heterogeneous, in part reflecting the local expertise at the institution performing the study as well as different patient population and study designs. An illustrative report that included 22 women who underwent surgery for fecal incontinence found that MRI correlated better with the surgical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/40\">",
"     40",
"    </a>",
"    ]. In contrast, another study of 52 patients reached different conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/41\">",
"     41",
"    </a>",
"    ]. The gold standard was a consensus opinion agreed upon by a gastroenterologist and surgeon after reviewing the history and all the imaging and physiologic studies. MRI and ultrasound were concordant in 32 patients; MRI was incorrect in 15 patients while ultrasound was incorrect in only 6 patients. Additional studies comparing the two modalities are needed to more clearly define each modality's strengths and weaknesses. However, ultrasound is less expensive and currently more widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Three-dimensional ultrasound (3D-EUS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional endoscopic ultrasound (3D-EUS) uses computer software to reconstruct standard EUS images into a 3D image. Although the data are somewhat mixed, a few studies have shown a benefit for 3D imaging in the evaluation of fecal incontinence. However, more studies are needed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 24 consecutive patients with sphincter injuries seen on regular EUS, 3D-EUS was able to demonstrate the radial angle of the IAS or EAS defect better than with standard EUS [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/11\">",
"       11",
"      </a>",
"      ]. This study showed that the length of the defect was strongly related to the angle of the tear.",
"     </li>",
"     <li>",
"      In a study of 18 patients with fecal incontinence, 3D-EUS was similar to MRI in detecting EAS atrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/42\">",
"       42",
"      </a>",
"      ]. However, the two imaging techniques did differ in their assessment of the severity of the atrophy with MRI labeling more patients with severe EAS atrophy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ULTRASOUND AND THE RESULTS OF SPHINCTEROPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the accuracy of endosonography had been established, a number of centers began using ultrasound to predict the therapeutic response after sphincteroplasty. Results of a number of small reports have been mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. Thus, the accuracy for predicting surgical outcomes remains uncertain. On the other hand, patients with improved continence after surgery also generally have improvement in the sphincter disruption visible on EUS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ENDOSONOGRAPHY AND INCONTINENCE RELATED TO CHILD BIRTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal delivery can result in fecal incontinence immediately or after many years. The most common injuries are anal sphincter tears or trauma to the pudendal nerve. In one series, anal sphincter tears were detected by anal endosonography in 35 percent of primiparous and 40 percent of multiparous women of whom symptoms of anal incontinence or fecal urgency were present in 13 and 23 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/47\">",
"     47",
"    </a>",
"    ]. Symptoms of urgency or incontinence usually developed within six weeks of delivery and were more likely in women who had forceps delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=see_link\">",
"     \"Fecal incontinence related to pregnancy and vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In another series, 13 of 59 (22 percent) previously nulliparous women reported altered fecal continence after their first delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/48\">",
"     48",
"    </a>",
"    ]. Eight had persistent symptoms during their second pregnancy, of whom seven worsened following delivery. Similar findings have been described in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data indicate that the damage that occurs with childbirth may remain clinically silent in the majority of women. However, these women are at risk for developing incontinence as they age or with future deliveries. Ultrasound may be helpful in screening women who are at risk of developing incontinence with future vaginal deliveries. Women who had previously had a forceps delivery, episiotomy, or a prolonged first",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    second stage of labor are more likely to have a sphincter defect [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/49\">",
"     49",
"    </a>",
"    ]. Delivery via cesarean section could be considered in high-risk patients to preserve continence especially if there is any evidence of symptoms (ie, minor soiling, incontinence for a brief period after the previous child birth, etc.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TECHNICAL ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical work-up for patients who present with fecal incontinence at our institution includes anal manometry and an endoscopy to exclude inflammatory bowel disease or malignancy followed immediately by endorectal EUS permitting assessment of the colonic mucosa and the anal sphincters during the same evaluation. Patients are given enemas per rectum until clear.",
"   </p>",
"   <p>",
"    Most centers use a rigid, rotating ultrasound probe with a plastic cap to conduct these examinations. We prefer to use a",
"    <span class=\"nowrap\">",
"     7.5/12",
"    </span>",
"    MHz radial scanning echoendoscope. The diameter of this scope is smaller than the traditional rigid rectal probe (12.7 mm versus 17 mm), which allows for less distortion of the anal canal. We grip the scope with one hand up against the anus to stabilize the scope within the anal canal. The examination is carried out with the patient in the left lateral position. For female patients, we occasionally perform the examination with the patient in the prone position in order to more clearly delineate the anterior aspect of the EAS. The St. Mark's group advocates this scanning position because they feel it provides more complete imaging of the anterior part of the EAS and improved visualization of the perineum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/51\">",
"     51",
"    </a>",
"    ]. A 10 cc water-filled syringe can be placed in the vagina to facilitate orientation in patients with more difficult imaging.",
"   </p>",
"   <p>",
"    Imaging is begun in the upper anal canal. At this point, the puborectalis can be visualized posteriorly as a hyperechoic sling. The EAS is not present anteriorly at this level. As the probe is slowly withdrawn, the EAS becomes apparent anteriorly in the mid anal canal. This is usually the area of maximal IAS thickness. Finally in the lower anal canal, only the subcutaneous aspect of the EAS is visualized.",
"   </p>",
"   <p>",
"    The examination is performed with the balloon minimally inflated (ie, just enough water to establish contact of the balloon with the anal canal) to reduce distortion of the anal canal during imaging. Several authors have proposed a transvaginal approach to eliminate any distortion of the anal canal during scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. However, in a study of 47 women conducted to determine the sensitivity of transvaginal ultrasound in detecting anal sphincter defects, the sensitivity of transvaginal ultrasound for IAS and EAS tears was only 44 and 48 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/55\">",
"     55",
"    </a>",
"    ]. The authors hypothesized that because the perineal body lies below the level of the vaginal introitus, only the proximal anal canal can be imaged in a plane parallel to its axis. In addition, the echoendoscope has a diameter of only 12.7 mm. This causes only minimal, if any, distortion of the anal canal. Thus, a transvaginal approach is not necessary.",
"   </p>",
"   <p>",
"    IAS tears appear as hyperechoic breaks in the normally hypoechoic ring in contrast to EAS tears, which appear as relatively hypoechoic areas in the normally hyperechoic ring. This corresponds to replacement of the normal striated muscle with granulation tissue and fibrosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69420 \" href=\"UTD.htm?22/43/23219\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The results obtained with rectal EUS are somewhat dependent upon the operator's experience. However, it is fairly easy to learn and intra and inter-observer variability is low [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21735/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/50/38690?source=see_link\">",
"       \"Patient information: Fecal incontinence (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/55/6006?source=see_link\">",
"       \"Patient information: Fecal incontinence (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endorectal endoscopic ultrasound (EUS) is a well-tolerated and sensitive means of detecting anal sphincter defects in patients with fecal incontinence. As a result, it has largely replaced electromyography (EMG) for this purpose. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Endorectal ultrasound and EMG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      3D-EUS may offer an advantage over standard rectal ultrasound, but additional studies are needed to confirm this benefit. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Three-dimensional ultrasound (3D-EUS)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EUS can be used to predict the therapeutic response to sphincteroplasty. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Ultrasound and the results of sphincteroplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EUS can detect a sphincter injury in up to 35 percent of women who delivered vaginally, potentially providing a means to identify women at high-risk for development of incontinence after additional deliveries. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Endosonography and incontinence related to child birth'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/1\">",
"      Marzio L, Ciccaglione FA, Falcucci M, et al. Relationship between anal canal diameter and pressure evaluated simultaneously by endosonography and manometry in normal human subjects. Int J Colorectal Dis 1998; 13:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/2\">",
"      Nielsen MB, Hauge C, Rasmussen OO, et al. Anal sphincter size measured by endosonography in healthy volunteers. Effect of age, sex, and parity. Acta Radiol 1992; 33:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/3\">",
"      Nielsen MB. Endosonography of the anal sphincter muscles in healthy volunteers and in patients with defecation disorders. Acta Radiol Suppl 1998; 416:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/4\">",
"      Gantke B, Sch&auml;fer A, Enck P, L&uuml;bke HJ. Sonographic, manometric, and myographic evaluation of the anal sphincters morphology and function. Dis Colon Rectum 1993; 36:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/5\">",
"      Burnett SJ, Bartram CI. Endosonographic variations in the normal internal anal sphincter. Int J Colorectal Dis 1991; 6:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/6\">",
"      Papachrysostomou M, Pye SD, Wild SR, Smith AN. Anal endosonography in asymptomatic subjects. Scand J Gastroenterol 1993; 28:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/7\">",
"      Sultan AH, Nicholls RJ, Kamm MA, et al. Anal endosonography and correlation with in vitro and in vivo anatomy. Br J Surg 1993; 80:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/8\">",
"      Wong RF, Bonapace ES Jr, Chung CY, et al. Simultaneous endoluminal sonography and manometry to assess anal sphincter complex in normal subjects. Dig Dis Sci 1998; 43:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/9\">",
"      Sultan AH, Kamm MA, Hudson CN, et al. Endosonography of the anal sphincters: normal anatomy and comparison with manometry. Clin Radiol 1994; 49:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/10\">",
"      Falk PM, Blatchford GJ, Cali RL, et al. Transanal ultrasound and manometry in the evaluation of fecal incontinence. Dis Colon Rectum 1994; 37:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/11\">",
"      Gold DM, Bartram CI, Halligan S, et al. Three-dimensional endoanal sonography in assessing anal canal injury. Br J Surg 1999; 86:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/12\">",
"      Oh C, Kark AE. Anatomy of the external anal sphincter. Br J Surg 1972; 59:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/13\">",
"      Law PJ, Kamm MA, Bartram CI. A comparison between electromyography and anal endosonography in mapping external anal sphincter defects. Dis Colon Rectum 1990; 33:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/14\">",
"      Law PJ, Kamm MA, Bartram CI. Anal endosonography in the investigation of faecal incontinence. Br J Surg 1991; 78:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/15\">",
"      Burnett SJ, Speakman CT, Kamm MA, Bartram CI. Confirmation of endosonographic detection of external anal sphincter defects by simultaneous electromyographic mapping. Br J Surg 1991; 78:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/16\">",
"      Damon H, Henry L, Valette PJ, Mion F. [Incidence of sphincter ruptures in anal incontinence: ultrasound study]. Ann Chir 2000; 125:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/17\">",
"      Sailer M, Leppert R, Fuchs KH, Thiede A. [Endo-anal sonography in diagnosis of fecal incontinence]. Zentralbl Chir 1996; 121:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/18\">",
"      Farouk R, Bartolo DC. The use of endoluminal ultrasound in the assessment of patients with faecal incontinence. J R Coll Surg Edinb 1994; 39:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/19\">",
"      Roche B, Marti MC. [Value of endo-anal ultrasonography in the assessment of anal incontinence]. Schweiz Med Wochenschr Suppl 1996; 79:64S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/20\">",
"      Eckardt VF, Jung B, Fischer B, Lierse W. Anal endosonography in healthy subjects and patients with idiopathic fecal incontinence. Dis Colon Rectum 1994; 37:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/21\">",
"      Rieger NA, Sweeney JL, Hoffmann DC, et al. Investigation of fecal incontinence with endoanal ultrasound. Dis Colon Rectum 1996; 39:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/22\">",
"      Karoui S, Savoye-Collet C, Koning E, et al. Prevalence of anal sphincter defects revealed by sonography in 335 incontinent patients and 115 continent patients. AJR Am J Roentgenol 1999; 173:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/23\">",
"      Liberman H, Faria J, Ternent CA, et al. A prospective evaluation of the value of anorectal physiology in the management of fecal incontinence. Dis Colon Rectum 2001; 44:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/24\">",
"      Voyvodic F, Rieger NA, Skinner S, et al. Endosonographic imaging of anal sphincter injury: does the size of the tear correlate with the degree of dysfunction? Dis Colon Rectum 2003; 46:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/25\">",
"      Fowler AL, Mills A, Virjee J, et al. Comparison of ultrasound and manometric sphincter length and incontinence scores. Dis Colon Rectum 2003; 46:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/26\">",
"      Damon H, Henry L, Barth X, Mion F. Fecal incontinence in females with a past history of vaginal delivery: significance of anal sphincter defects detected by ultrasound. Dis Colon Rectum 2002; 45:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/27\">",
"      Mart&iacute;nez Hern&aacute;ndez Magro P, Villanueva S&aacute;enz E, Jaime Zavala M, et al. Endoanal sonography in assessment of fecal incontinence following obstetric trauma. Ultrasound Obstet Gynecol 2003; 22:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/28\">",
"      Tankova L, Draganov V, Damyanov N. Endosonography for assessment of anorectal changes in patients with fecal incontinence. Eur J Ultrasound 2001; 12:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/29\">",
"      Barthet M, Bellon P, Abou E, et al. Anal endosonography for assessment of anal incontinence with a linear probe: relationships with clinical and manometric features. Int J Colorectal Dis 2002; 17:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/30\">",
"      Beer-Gabel M, Teshler M, Barzilai N, et al. Dynamic transperineal ultrasound in the diagnosis of pelvic floor disorders: pilot study. Dis Colon Rectum 2002; 45:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/31\">",
"      Williams AB, Spencer JA, Bartram CI. Assessment of third degree tears using three-dimensional anal endosonography with combined anal manometry: a novel technique. BJOG 2002; 109:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/32\">",
"      Shobeiri SA, Nolan TE, Yordan-Jovet R, et al. Digital examination compared to trans-perineal ultrasound for the evaluation of anal sphincter repair. Int J Gynaecol Obstet 2002; 78:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/33\">",
"      Gravante G, Giordano P. The role of three-dimensional endoluminal ultrasound imaging in the evaluation of anorectal diseases: a review. Surg Endosc 2008; 22:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/34\">",
"      Sentovich SM, Blatchford GJ, Rivela LJ, et al. Diagnosing anal sphincter injury with transanal ultrasound and manometry. Dis Colon Rectum 1997; 40:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/35\">",
"      Meyenberger C, Bertschinger P, Zala GF, Buchmann P. Anal sphincter defects in fecal incontinence: correlation between endosonography and surgery. Endoscopy 1996; 28:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/36\">",
"      Deen KI, Kumar D, Williams JG, et al. Anal sphincter defects. Correlation between endoanal ultrasound and surgery. Ann Surg 1993; 218:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/37\">",
"      Sultan AH, Kamm MA, Talbot IC, et al. Anal endosonography for identifying external sphincter defects confirmed histologically. Br J Surg 1994; 81:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/38\">",
"      Sch&auml;fer R, Heyer T, Gantke B, et al. Anal endosonography and manometry: comparison in patients with defecation problems. Dis Colon Rectum 1997; 40:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/39\">",
"      Papachrysostomou M, Pye SD, Wild SR, Smith AN. Significance of the thickness of the anal sphincters with age and its relevance in faecal incontinence. Scand J Gastroenterol 1994; 29:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/40\">",
"      Rociu E, Stoker J, Eijkemans MJ, et al. Fecal incontinence: endoanal US versus endoanal MR imaging. Radiology 1999; 212:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/41\">",
"      Malouf AJ, Williams AB, Halligan S, et al. Prospective assessment of accuracy of endoanal MR imaging and endosonography in patients with fecal incontinence. AJR Am J Roentgenol 2000; 175:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/42\">",
"      Cazemier M, Terra MP, Stoker J, et al. Atrophy and defects detection of the external anal sphincter: comparison between three-dimensional anal endosonography and endoanal magnetic resonance imaging. Dis Colon Rectum 2006; 49:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/43\">",
"      Felt-Bersma RJ, Cuesta MA, Koorevaar M. Anal sphincter repair improves anorectal function and endosonographic image. A prospective clinical study. Dis Colon Rectum 1996; 39:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/44\">",
"      Ternent CA, Shashidharan M, Blatchford GJ, et al. Transanal ultrasound and anorectal physiology findings affecting continence after sphincteroplasty. Dis Colon Rectum 1997; 40:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/45\">",
"      Savoye-Collet C, Savoye G, Koning E, et al. Anal endosonography after sphincter repair: specific patterns related to clinical outcome. Abdom Imaging 1999; 24:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/46\">",
"      Hill K, Fanning S, Fennerty MB, Faigel DO. Endoanal ultrasound compared to anorectal manometry for the evaluation of fecal incontinence: a study of the effect these tests have on clinical outcome. Dig Dis Sci 2006; 51:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/47\">",
"      Sultan AH, Kamm MA, Bartram CI, Hudson CN. Anal sphincter trauma during instrumental delivery. Int J Gynaecol Obstet 1993; 43:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/48\">",
"      Fynes M, Donnelly V, Behan M, et al. Effect of second vaginal delivery on anorectal physiology and faecal continence: a prospective study. Lancet 1999; 354:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/49\">",
"      Abramowitz L, Sobhani I, Ganansia R, et al. Are sphincter defects the cause of anal incontinence after vaginal delivery? Results of a prospective study. Dis Colon Rectum 2000; 43:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/50\">",
"      Burnett SJ, Spence-Jones C, Speakman CT, et al. Unsuspected sphincter damage following childbirth revealed by anal endosonography. Br J Radiol 1991; 64:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/51\">",
"      Frudinger A, Bartram CI, Halligan S, Kamm M. Examination techniques for endosonography of the anal canal. Abdom Imaging 1998; 23:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/52\">",
"      Sultan AH, Loder PB, Bartram CI, et al. Vaginal endosonography. New approach to image the undisturbed anal sphincter. Dis Colon Rectum 1994; 37:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/53\">",
"      Poen AC, Felt-Bersma RJ, Cuesta MA, Meuwissen GM. Vaginal endosonography of the anal sphincter complex is important in the assessment of faecal incontinence and perianal sepsis. Br J Surg 1998; 85:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/54\">",
"      Stewart LK, Wilson SR. Transvaginal sonography of the anal sphincter: reliable, or not? AJR Am J Roentgenol 1999; 173:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/55\">",
"      Frudinger A, Bartram CI, Kamm MA. Transvaginal versus anal endosonography for detecting damage to the anal sphincter. AJR Am J Roentgenol 1997; 168:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21735/abstract/56\">",
"      Gold DM, Halligan S, Kmiot WA, Bartram CI. Intraobserver and interobserver agreement in anal endosonography. Br J Surg 1999; 86:371.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2667 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21735=[""].join("\n");
var outline_f21_14_21735=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL ULTRASOUND APPEARANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ENDORECTAL ULTRASOUND AND EMG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TEST CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ULTRASOUND AND MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Three-dimensional ultrasound (3D-EUS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ULTRASOUND AND THE RESULTS OF SPHINCTEROPLASTY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ENDOSONOGRAPHY AND INCONTINENCE RELATED TO CHILD BIRTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TECHNICAL ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2667\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2667|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/54/28516\" title=\"diagnostic image 1\">",
"      EUS anorectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/43/23219\" title=\"diagnostic image 2\">",
"      EAS defect EUS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=related_link\">",
"      Fecal incontinence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=related_link\">",
"      Fecal incontinence related to pregnancy and vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/55/6006?source=related_link\">",
"      Patient information: Fecal incontinence (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/50/38690?source=related_link\">",
"      Patient information: Fecal incontinence (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_14_21736="Overview of vitamin A";
var content_f21_14_21736=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of vitamin A",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/14/21736/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21736/contributors\">",
"     Sassan Pazirandeh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21736/contributors\">",
"     David L Burns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/14/21736/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21736/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21736/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/14/21736/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21736/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/14/21736/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamins are a number of chemically unrelated families of organic substances that cannot be synthesized by humans and must be ingested in the diet in small quantities to facilitate normal metabolism. They are divided into water-soluble and fat-soluble vitamins (",
"    <a class=\"graphic graphic_table graphicRef63827 \" href=\"UTD.htm?12/15/12541\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Ancient Egyptians recognized that night blindness could be treated by consumption of liver [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/1\">",
"     1",
"    </a>",
"    ]. In the late 1920s, through the efforts of a Swiss scientist named Karrer and his colleagues, the fat-soluble compound in liver was isolated and termed vitamin A&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will focus on issues related to vitamin A. Overviews of the other fat-soluble vitamins, minerals and water-soluble vitamins are available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=see_link\">",
"     \"Overview of vitamin D\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28871?source=see_link\">",
"     \"Overview of vitamin E\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=see_link\">",
"     \"Overview of vitamin K\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link\">",
"     \"Overview of dietary trace minerals\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=see_link\">",
"     \"Overview of water-soluble vitamins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHEMISTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin A is a subclass of a family of lipid-soluble compounds referred to as retinoic acids. These consist of four isoprenoid units joined in a head to tail fashion. There are two main forms of vitamin A: provitamin A carotenoids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    and others), and preformed vitamin A.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provitamin A carotenoids are found in plants. There are many forms of provitamin A, but",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      is only one that is metabolized by mammals into vitamin A.",
"     </li>",
"     <li>",
"      Preformed vitamin A (retinol, retinal, retinoic acid, and retinyl esters) is the most active form of vitamin A; it is mostly found in animal sources of food and is also the form supplied by most supplements. Some supplements provide a combination of provitamin A (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      ) and preformed vitamin A. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common food sources of preformed vitamin A (retinols) are liver, kidney, egg yolk, and butter. Provitamin A (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    ) is mostly found in green leafy vegetables, sweet potato and carrots. Because vitamin A from animal sources or supplements is preformed, it is more likely to cause toxicity than the provitamin A from plant sources. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Metabolism'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Excess'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial steps in metabolism depend on the type of vitamin A ingested. The metabolism of provitamin A (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    ) into active vitamin A is a highly regulated step, so excessive intake of vitamin A from plant sources is very unlikely to cause toxicity. By contrast, absorption and storage of preformed vitamin A (eg, in animal liver or dietary supplements) is efficient, and toxicity can occur if excessive quantities are ingested. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Excess'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provitamin A (mostly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      , from plant sources), must be cleaved to retinal before absorption. This step is subject to feedback regulation, which depends on vitamin A status.",
"     </li>",
"     <li>",
"      Preformed vitamin A (retinol, retinal, retinoic acid, and retinyl esters, from supplements or animal sources) is hydrolyzed into retinol in the lumen of the small intestine. A number of retinyl ester hydrolases are involved in this process at the level of the mucosal brush-border [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/3\">",
"       3",
"      </a>",
"      ]. It also appears that pancreatic enzymes have a role in retinoid assimilation [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/4\">",
"       4",
"      </a>",
"      ]. Bile salts form micelles which allow water solubilization of the products of lipolysis and absorption through the intestinal mucosa. These steps are highly efficient and not subject to feedback regulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Within the small intestine, retinols are re-esterified into retinyl-esters, incorporated into chylomicrons, and excreted into lymphatics and plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/2\">",
"     2",
"    </a>",
"    ]. In the blood, chylomicrons are then broken down into multiple remnants including apolipoproteins B and E, which contain retinol esters.",
"   </p>",
"   <p>",
"    The apolipoproteins are then taken up by the liver via a receptor-mediated endocytosis on the surface of the hepatocytes, and the retinol esters are released [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/2\">",
"     2",
"    </a>",
"    ]. These are further metabolized to eventually combine with Retinol Binding Proteins (RBP) before storage in vitamin A-containing lipid globules within the hepatic stellate cells (formerly known as Ito cells).",
"   </p>",
"   <p>",
"    About 50 to 85 percent of the total body retinol is stored in the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/5\">",
"     5",
"    </a>",
"    ]. It is also found in many other tissues in much smaller concentrations. In order for vitamin A to reach its target organs, it binds to RBP molecules for release into plasma as a retinol-RBP complex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin A has a number of biologic actions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vision",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the eye, vitamin A has two major roles: prevention of xerophthalmia (abnormalities in corneal and conjunctival development) and phototransduction.",
"   </p>",
"   <p>",
"    Two types of retinal photoreceptor cells are involved in the visual process. The cone cells are responsible for the absorption of light and color vision in bright light. The rod cells detect motion and are responsible for night-vision. In the rod cells of the retina, all-trans-retinol is converted to 11-cis-retinol, which then combines with a membrane-bound protein called opsin to yield rhodopsin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/6\">",
"     6",
"    </a>",
"    ]. A similar type of reaction occurs in the cone cells of the retina to produce iodopsin. The visual pigments absorb light at different wavelengths depending upon the type of cone cells. As an example, the red-sensitive cone cells absorb any light stimulus in the wavelength of the color red. This leads to the absorption of the three basic colors, red, green, and blue. The light-activated transformation of these complexes leads to a cascade of hyperpolarization of rod cell membrane, therefore enabling the transmission of light stimuli to the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cellular differentiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than its importance in vision, vitamin A is crucial to cellular differentiation and integrity in the eye. All the cells in the conjunctiva and the retina have RBPs, suggesting the dependence of these tissues on retinoic acid. Normal fetal development of the eye also requires adequate vitamin A intake and stores [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/7\">",
"     7",
"    </a>",
"    ]. A number of studies in vitamin A depleted animals show abnormal fetal eye tissue development [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin A deficiency is rarely seen in the United States and other industrialized countries. However, it is still the third most common nutritional deficiency in the world [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/9\">",
"     9",
"    </a>",
"    ]. In a large part of the third world (Southern and Southeast Asia, Africa, and South America), night blindness, complete blindness, and advanced stages of xerophthalmia occur in many malnourished children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/10\">",
"     10",
"    </a>",
"    ]. This represents a major public health problem; approximately 500,000 preschool children become blind each year and many die [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/11\">",
"     11",
"    </a>",
"    ]. Routine distribution of vitamin A to children in endemic areas prevents these ophthalmic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/12,13\">",
"     12,13",
"    </a>",
"    ] and has other important benefits: In a meta-analysis of 43 randomized controlled trials conducted in low- and mid-income countries, vitamin A supplementation given to children between six months and five years of age was associated with a 24 percent reduction in all-cause mortality and a 28 percent reduction in diarrhea-associated mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In addition, one study suggests that vitamin A supplementation to children in undernourished populations reduces the long-term risk of hearing loss among those with ear discharge (a marker for otitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/16\">",
"     16",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Vitamin A deficiency with or without xerophthalmia can also be seen in patients with disorders associated with fat malabsorption, such as cystic fibrosis, celiac disease, cholestatic liver disease such as primary biliary cirrhosis, small bowel Crohn's disease, and pancreatic insufficiency; xerophthalmia also has been reported in the developed world in individuals with extremely limited diets due to mental health disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=see_link&amp;anchor=H8#H8\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\", section on 'Vitamin A'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=see_link&amp;anchor=H15#H15\">",
"     \"Cystic fibrosis: Nutritional issues\", section on 'Vitamin A'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of vitamin A deficiency is usually made by clinical findings, but can be supported by measurement of serum retinol levels (levels less than 20",
"    <span class=\"nowrap\">",
"     micrograms/dL",
"    </span>",
"    suggest deficiency), or the ratio of retinol:RBP (a molar ratio &lt;0.8 suggests deficiency) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Serum carotene levels are correlated with vitamin A status, and low serum carotene can be used as a surrogate marker of malabsorption and nutritional status.",
"   </p>",
"   <p>",
"    Serum vitamin A concentrations do not reflect total vitamin A stores under certain conditions: Serum retinol levels may be artificially low (ie, underestimate vitamin A stores) in the setting of severe protein-calorie malnutrition because dietary protein, energy and zinc are required for synthesis of retinol binding protein (RBP) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/20\">",
"     20",
"    </a>",
"    ]. Similarly, serum retinol levels may be low during intercurrent infection because of transient decreases in the negative acute phase proteins including RBP. Conversely, in a patient with vitamin A deficiency, a dose of vitamin A may cause a transient rise in serum retinol concentrations, leading to overestimation of the patient's vitamin A stores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Xerophthalmia describes a spectrum of eye disease caused by vitamin A deficiency. It is characterized by pathologic dryness of the conjunctiva and cornea, caused by inadequate function of the lacrimal glands and is manifested by Bitot's spots (",
"      <a class=\"graphic graphic_picture graphicRef72148 \" href=\"UTD.htm?3/4/3136\">",
"       picture 1",
"      </a>",
"      ) (areas of abnormal squamous cell proliferation and keratinization of the conjunctiva), progressing to corneal xerosis (dryness) and keratomalacia (",
"      <a class=\"graphic graphic_picture graphicRef72297 \" href=\"UTD.htm?18/45/19156\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/7,21,22\">",
"       7,21,22",
"      </a>",
"      ]. Vitamin A deficiency also causes night blindness (nyctalopia) and retinopathy because vitamin A is a substrate for the photosensitive visual pigments in the retina. The advanced stages of xerophthalmia may be irreversible.",
"     </li>",
"     <li>",
"      Poor bone growth.",
"     </li>",
"     <li>",
"      Non-specific dermatological problems, such as hyperkeratosis, phrynoderma (follicular hyperkeratosis), and the destruction of hair follicles and their replacement with mucus-secreting glands [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Impairment of the humoral and cell mediated immune system via direct and indirect effects on the phagocytes and T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Supplementation with vitamin A at the community level in developing countries is recommended by the World Health Organization because of its beneficial effects on immunity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"       \"Vitamin supplementation in disease prevention\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin A deficiency is common among populations in developing countries. For populations in which vitamin A deficiency is endemic, the World Health Organization recommends the following replacement approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Periodic distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;To prevent clinical vitamin A deficiency in populations endemic for vitamin A deficiency, vitamin A supplements can be distributed at four to six month intervals at the following doses, where 1 microgram retinol = 3.3 International units (IU):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants &lt;6 months of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Non breast-fed: 50,000 IU orally",
"     </li>",
"     <li>",
"      Breast fed: 50,000 IU orally (unless the mother has received supplemental vitamin A)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants 6 to 12 months of age: 100,000 IU orally",
"     </li>",
"     <li>",
"      Children &gt;12 months of age: 200,000 IU orally",
"     </li>",
"     <li>",
"      Mothers: 200,000 IU orally, within eight weeks of delivery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women who may be pregnant who also require vitamin A replacement should not be given high-dose supplements because of potential teratogenic effects (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Teratogenic effects'",
"    </a>",
"    below), but should receive frequent small doses not exceeding 10,000 IU daily or 25,000 IU weekly. This corresponds approximately to the Upper Limit (UL) for adults set by the Food and Nutrition Board in the United States (",
"    <a class=\"graphic graphic_table graphicRef81151 \" href=\"UTD.htm?19/31/19967\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     High-dose supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children at high risk of vitamin A deficiency, such as those with measles, diarrhea, respiratory disease, or severe malnutrition, who live among populations at risk for vitamin A deficiency, and have not received supplements within the past 1 to 4 months, the WHO recommends a single dose of vitamin A at the age-specific dose listed above [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Xerophthalmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;For treatment of xerophthalmia, vitamin A is given in three doses at the age-specific doses listed above. The first dose is given immediately on diagnosis, the second on the following day, and the third dose at least two weeks later. Women of reproductive age or who are pregnant and have night blindness should be treated with frequent small doses of vitamin A (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Periodic distribution'",
"    </a>",
"    above). Those with xerophthalmia should be treated with the same high dose schedule as other adults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EXCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of the vitamin A toxicity cases are due to the chronic ingestion of large amounts of synthetic (or \"preformed\") vitamin A (about 10 times higher than the Recommended Dietary Allowance (RDA), or about 50,000 IU) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/25\">",
"     25",
"    </a>",
"    ]. Water-miscible, emulsified, and solid forms of retinol supplements, which include those in candy-like supplements marketed for children, are more toxic than oil-based preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, metabolism of provitamin A (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    , from plant sources) is highly regulated, so excessive ingestion of this form of vitamin A is very unlikely to cause toxicity. As an example, individuals who ingest large amounts of provitamin A (from plant sources) may develop yellow-tinged skin (carotenemia) without developing vitamin A toxicity. Carotenemia is particularly common among infants and toddlers who are eating large amounts of pureed vegetables (particularly carrots and green leafy vegetables), and may be initially confused with jaundice. The skin discoloration resolves spontaneously if the intake of these foods is reduced. Less commonly, carotenemia may also be caused by some diseases, including nephrosis, diabetes mellitus, anorexia nervosa, liver disease, and hypothyroidism, due to decreased conversion of beta carotene into retinol. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Metabolism'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34280?source=see_link&amp;anchor=H11#H11\">",
"     \"The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes\", section on 'Carotenemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three syndromes of vitamin A toxicity have been recognized: acute, chronic, and teratogenic. Large supplemental doses of retinol are very toxic to the liver, but due to the large storage capacity of the liver for vitamin A, the actual toxic doses are not well established [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of vitamin A toxicity consists of stopping vitamin A supplements and restricting vitamin A-rich foods (especially sources of pre-formed vitamin A, such as liver, kidney and egg yolk). If the patient has evidence of hepatotoxicity or pseudotumor cerebri, supportive treatment is indicated. Most case reports of chronic toxicity suggest gradual resolution of the symptoms after withdrawal of vitamin A, although hepatic fibrosis may persist [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Acute toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute toxicity occurs in adults when a single dose of &gt;660,000 IU (&gt;200,000 micrograms) of vitamin A is ingested. Symptoms include nausea, vomiting, vertigo, and blurry vision [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/25\">",
"     25",
"    </a>",
"    ]. In very high doses, drowsiness, malaise, and recurrent vomiting can follow the initial symptoms listed above. In infants under six months of age, as little as 20,000 IU (6000 micrograms) given briefly (eg, for one month or less) may produce toxic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chronic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic toxicity occurs with long-term ingestion of vitamin A doses in amounts higher than 10 times the RDA (ie, toxicity may occur with chronic ingestion of about 33,000 IU [10,000 micrograms] of retinol in adults) (",
"    <a class=\"graphic graphic_table graphicRef81151 \" href=\"UTD.htm?19/31/19967\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/31\">",
"     31",
"    </a>",
"    ]. Some toxic effects of vitamin A also have been observed in infants fed large amounts of chicken liver containing 300 IU (90 micrograms retinol) for one month or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/32\">",
"     32",
"    </a>",
"    ]. Signs of chronic toxicity include ataxia, alopecia, hyperlipidemia, hepatotoxicity, bone and muscle pain, visual impairments, and many other non-specific signs and symptoms.",
"   </p>",
"   <p>",
"    Because most vitamin A is stored in the liver, circulating serum levels of vitamin A (retinol) are not helpful in diagnosing vitamin A toxicity. Patients with hypervitaminosis A may have low, normal, or high serum levels of retinol, depending on the timing, quantity, and form of vitamin A ingested, and the patient's age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum retinyl esters in the fasting state are sometimes used as a marker for chronic hypervitaminosis A; retinyl ester concentrations &gt;10 percent of the total vitamin A pool is considered abnormal (ie, a molar ratio of plasma retinyl esters to the sum of plasma retinol and retinyl esters) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. However, this ratio may still not reflect hepatic stores long after the toxic ingestion has stopped. Elevated serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcium have been reported.",
"   </p>",
"   <p>",
"    Symptoms and signs of toxicity include dry skin, nausea, headache, fatigue, irritability, hepatomegaly, alopecia, hyperostosis, and increased cerebrospinal fluid pressure (pseudotumor cerebri). Although children with cystic fibrosis are at risk for fat-soluble vitamin deficiency due to their pancreatic insufficiency, standard supplementation regimens may lead to excessive levels of vitamin A. In one study of children with CF who were given standard supplements, total vitamin A intake and serum retinol values were elevated, raising concerns about the possibility of chronic toxicity which may contribute to CF-associated liver and bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=see_link&amp;anchor=H15#H15\">",
"     \"Cystic fibrosis: Nutritional issues\", section on 'Vitamin A'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatotoxicity can lead to cirrhosis and has been associated with veno-occlusive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/27,34\">",
"     27,34",
"    </a>",
"    ]. A prominent histologic finding is the proliferation of hepatic stellate cells. Several factors can increase the toxicity of vitamin A, including underlying liver and kidney disease, alcoholism, and the use of some drugs, such as tetracyclines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Adverse effects on bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that intake levels of vitamin A in the high-normal range may have adverse effects on bone health. In a prospective cohort study of postmenopausal women, long-term intake of a diet high in retinol (vitamin A) was associated with an increased risk of osteoporotic fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/39\">",
"     39",
"    </a>",
"    ]. Similarly, high serum retinol levels were associated with an increased fracture risk in men [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/40\">",
"     40",
"    </a>",
"    ]. Thus high doses of vitamin A may compromise bone health, but the threshold at which clinically relevant effects are seen remains to be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link&amp;anchor=H9#H9\">",
"     \"Drugs that affect bone metabolism\", section on 'Vitamin A and synthetic retinoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Teratogenic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinoic acid has been known to be very teratogenic in the first trimester of pregnancy, leading to spontaneous abortions and fetal malformations, including microcephaly and cardiac anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/31\">",
"     31",
"    </a>",
"    ]. Effects may occur at doses only several times the RDA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/42\">",
"     42",
"    </a>",
"    ]. Many animal models as well as human studies have shown high incidence of birth defects in mothers who ingested therapeutic doses of retinoic acid for dermatological uses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/31\">",
"     31",
"    </a>",
"    ]. A safe upper limit for vitamin A intake during pregnancy has been recognized at about 10,000 IU daily (about 3000 micrograms) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     THERAPEUTIC USES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinoic acid and carotenoids have several therapeutic uses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Measles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin A treatment of children with measles infection in developing countries appears to reduce complications and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/43\">",
"     43",
"    </a>",
"    ]. Thus, vitamin A treatment is recommended for children with measles in developing countries and other areas in which vitamin A deficiency is endemic, and in selected circumstances in developed countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22793?source=see_link&amp;anchor=H45#H45\">",
"     \"Prevention and treatment of measles\", section on 'Vitamin A'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Dermatology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinoic acid has been used for many hyperkeratotic and hyperproliferative disorders of skin. Synthetic oxidative metabolites of vitamin A such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    can be used topically or systemically for treatment of a variety of skin disorders. Systemic forms have been used in some forms of psoriasis and other disorders of keratinization and even skin cancer. 13-cis-retinoic acid reduces the proliferation of sebaceous glands, and due to such properties it is used for treatment of acne and acne-related disorders. At the lower range of the toxic dose, some of the conjugated forms of retinoic acids (ie, retinol beta-glucoronide) have been used as topical creams or ointments for hyperpigmentation or for reducing wrinkling associated with sun exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because carotenoids are antioxidants, they were investigated for possible prevention of cardiovascular disease. However, randomized trials of vitamin A and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    have shown no benefit for primary or secondary prevention of coronary heart disease; furthermore, there is some evidence that beta-carotene supplementation may increase mortality from cardiovascular disease and may increase the risk of lung and colon cancer. Therefore, in industrialized countries where dietary intake of vitamin A is generally adequate, supplementing with vitamin A for disease prevention is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Acute promyelocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;All-trans-retinoic acid (ATRA, or tretinoin) is a synthetic oxidative metabolite of retinoic acid and has been used in acute promyelocytic leukemia (a subgroup of acute myelocytic leukemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial studies demonstrated a remarkable response to high-dose daily treatment with all-trans-retinoic acid (about 45",
"    <span class=\"nowrap\">",
"     mg/m2/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/45\">",
"     45",
"    </a>",
"    ]. However, later experience demonstrated that such high doses can lead to a dangerous condition known as the \"differentiation syndrome\" (previously \"retinoic acid syndrome\") characterized by respiratory distress, fevers, kidney failure, and hypotension. Because a large number of patients who developed this have died, the drug is administered for short periods of time, in conjunction with other standard chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=see_link\">",
"     \"Differentiation (retinoic acid) syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     REQUIREMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     General population",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended daily allowance (RDA) for vitamin A is given as retinol activity equivalents (RAE), where one RAE = 1 microgram retinol or 3.3 IU.",
"   </p>",
"   <p>",
"    The RDA for adult males is 3000 IU (900 micrograms retinol) daily, and for females 2300 IU (700 micrograms retinol) daily. The RDA for other groups is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef81151 \" href=\"UTD.htm?19/31/19967\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with clinically significant fat malabsorption due to pancreatic insufficiency or other digestive disorders are at risk for deficiency of vitamin A and other fat-soluble vitamins. Patients with cystic fibrosis are routinely treated with supplements of fat-soluble vitamins which provide doses that are several fold higher than the RDA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=see_link&amp;anchor=H14#H14\">",
"     \"Cystic fibrosis: Nutritional issues\", section on 'Fat soluble vitamins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with chronic liver disease are typically treated with a standard multivitamin which includes vitamin A. If vitamin A deficiency is detected in these patients, standard replacement doses should be given. High levels of alcohol consumption appear to potentiate the hepatotoxic effects of vitamin A [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with marked cholestasis may require higher doses of vitamin A and other fat-soluble vitamins in order to maintain adequate levels. Children with cholestatic liver disease often require between 5,000 and 25,000 IU (1500-7500 micrograms retinol) daily of water-miscible vitamin A [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. For patients treated with these high doses of vitamin A, monitoring for clinical or laboratory evidence of vitamin A toxicity (usually assayed as serum retinyl esters in the fasting state) is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21736/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Replacement'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6889?source=see_link\">",
"     \"Nutritional assessment in chronic liver disease\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17\">",
"     'Chronic toxicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitamin A is a subclass of a family of lipid-soluble compounds referred to as retinoic acids. Because vitamin A from animal sources or supplements (eg, retinol) is preformed, it is more likely to cause toxicity than the provitamin A from plant sources (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Chemistry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin A crucial to cellular differentiation and integrity in the eye, and deficiency causes xerophthalmia (dryness, fragility and clouding of the cornea) (",
"      <a class=\"graphic graphic_picture graphicRef72297 \" href=\"UTD.htm?18/45/19156\">",
"       picture 2",
"      </a>",
"      ). Vitamin A also has an important role in phototransduction, and deficiency causes night blindness. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Actions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin A deficiency is also associated with poor bone growth, nonspecific dermatological problems (eg, hyperkeratosis), and impaired immune function. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin A deficiency is common among populations in developing countries, and effective replacement approaches have been defined for at-risk populations. Additional doses are given to individuals with xerophthalmia or children at high risk of vitamin A deficiency, such as those with measles, diarrhea, respiratory disease, or severe malnutrition. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Replacement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of vitamin A deficiency is usually made by clinical findings, but can be supported by measurement of serum retinol levels, or the ratio of retinol:RBP (a molar ratio &lt;0.8 suggests deficiency). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In populations where dietary intake of vitamin A is adequate, there is no evidence that supplementation of vitamin A is helpful for preventing cardiovascular disease, and supplementation may even have harmful effects on cardiovascular mortality, cancer, and bone health. Therefore, in industrialized countries where dietary intake of vitamin A is generally adequate, we recommend NOT supplementing vitamin A for disease prevention (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Atherosclerosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H19#H19\">",
"       \"Vitamin supplementation in disease prevention\", section on 'Vitamin A and the carotenoids'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Acute vitamin A toxicity occurs in adults when a single dose of &gt;660,000 units (&gt;200 mg) of vitamin A is ingested. Chronic toxicity occurs with long-term ingestion of vitamin A doses in amounts higher than 10 times the RDA. Preformed vitamin A can have teratogenic effects during the first trimester of pregnancy, at doses of only several times the RDA. Circulating serum levels of vitamin A (retinol) are not helpful in diagnosing vitamin A toxicity, but measurement of serum retinyl esters may be helpful. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Excess'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/1\">",
"      Wolf G. A history of vitamin A and retinoids. FASEB J 1996; 10:1102.",
"     </a>",
"    </li>",
"    <li>",
"     Ross AC. Vitamin A and Retinoids. In: Modern Nutrition in Health and Disease, Shils M, Olson J, Shike M (Eds), Lippincott, Philadelphia 2000. p.305.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/3\">",
"      Harrison EH. Enzymes catalyzing the hydrolysis of retinyl esters. Biochim Biophys Acta 1993; 1170:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/4\">",
"      Rigtrup KM, Ong DE. A retinyl ester hydrolase activity intrinsic to the brush border membrane of rat small intestine. Biochemistry 1992; 31:2920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/5\">",
"      Green MH, Green JB, Berg T, et al. Changes in hepatic parenchymal and nonparenchymal cell vitamin A content during vitamin A depletion in the rat. J Nutr 1988; 118:1331.",
"     </a>",
"    </li>",
"    <li>",
"     Saari JC. Retinoids in photosensitive systems. In: The retinoids: Biology, chemistry, and medicine, Sporn MB, Roberts AB, Goodman DS (Eds), Raven Press, New York 1994. p.351.",
"    </li>",
"    <li>",
"     Sommer A, West KP Jr. Vitamin A deficiency: Health, survival, and vision, Oxford University press, New York 1996. p.130.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/8\">",
"      Morriss-Kay GM, Sokolova N. Embryonic development and pattern formation. FASEB J 1996; 10:961.",
"     </a>",
"    </li>",
"    <li>",
"     Williams SR. Nutrition and diet therapy, 8th, Mosby, St Louis 1997. p.159.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/10\">",
"      Janczewska I, Ericzon BG, Eriksson LS. Influence of orthotopic liver transplantation on serum vitamin A levels in patients with chronic liver disease. Scand J Gastroenterol 1995; 30:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/11\">",
"      Underwood BA, Arthur P. The contribution of vitamin A to public health. FASEB J 1996; 10:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/12\">",
"      Swami HM, Thakur JS, Bhatia SP. Impact of mass supplementation of vitamin A. Indian J Pediatr 2007; 74:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/13\">",
"      Katz J, West KP Jr, Khatry SK, et al. Impact of vitamin A supplementation on prevalence and incidence of xerophthalmia in Nepal. Invest Ophthalmol Vis Sci 1995; 36:2577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/14\">",
"      Imdad A, Herzer K, Mayo-Wilson E, et al. Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age. Cochrane Database Syst Rev 2010; :CD008524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/15\">",
"      Mayo-Wilson E, Imdad A, Herzer K, et al. Vitamin A supplements for preventing mortality, illness, and blindness in children aged under 5: systematic review and meta-analysis. BMJ 2011; 343:d5094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/16\">",
"      Schmitz J, West KP Jr, Khatry SK, et al. Vitamin A supplementation in preschool children and risk of hearing loss as adolescents and young adults in rural Nepal: randomised trial cohort follow-up study. BMJ 2012; 344:d7962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/17\">",
"      Lin P, Fintelmann RE, Khalifa YM, et al. Ocular surface disease secondary to vitamin A deficiency in the developed world: it still exists. Arch Ophthalmol 2011; 129:798.",
"     </a>",
"    </li>",
"    <li>",
"     Feranchak AP, and Sokol RJ. Medical and nutritional management of cholestasis in infants and children. In: Liver Disease in Children, 3rd, Suchy FJ, Sokol RJ, and Balistreri WF (Eds), Cambridge University Press, New York 2007. p.208.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/19\">",
"      de Pee S, Dary O. Biochemical indicators of vitamin A deficiency: serum retinol and serum retinol binding protein. J Nutr 2002; 132:2895S.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board of the Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc (2000). National Academies Press, Washington DC, 2000. p. 162-196. Available at: file://books.nap.edu/openbook.php?isbn=0309072794 (Accessed 4/22/10).",
"    </li>",
"    <li>",
"     Morgan SL, Weinsier RL. Fundamentals of clinical nutrition, Mosby, St Louis 1998. p.3.",
"    </li>",
"    <li>",
"     WHO/UNICEF/IVACG Task Force. Vitamin A supplements; a guide to their use in the treatment and prevention of vitamin A deficiency and xerophthalmia, 2nd Ed. World Health Organization, Geneva, 1997. CHF 9.80. Available at: file://www.who.int/nutrition/publications/micronutrients/vitamin_a_deficieny/9241545062/en/ (Accessed 6/2/10).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/23\">",
"      Cantorna MT, Nashold FE, Hayes CE. Vitamin A deficiency results in a priming environment conducive for Th1 cell development. Eur J Immunol 1995; 25:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/24\">",
"      Cantorna MT, Nashold FE, Chun TY, Hayes CE. Vitamin A down-regulation of IFN-gamma synthesis in cloned mouse Th1 lymphocytes depends on the CD28 costimulatory pathway. J Immunol 1996; 156:2674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/25\">",
"      Biesalski HK. Comparative assessment of the toxicology of vitamin A and retinoids in man. Toxicology 1989; 57:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/26\">",
"      Myhre AM, Carlsen MH, B&oslash;hn SK, et al. Water-miscible, emulsified, and solid forms of retinol supplements are more toxic than oil-based preparations. Am J Clin Nutr 2003; 78:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/27\">",
"      Geubel AP, De Galocsy C, Alves N, et al. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology 1991; 100:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/28\">",
"      Guarascio P, Portmann B, Visco G, Williams R. Liver damage with reversible portal hypertension from vitamin A intoxication: demonstration of Ito cells. J Clin Pathol 1983; 36:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/29\">",
"      Weber FL Jr, Mitchell GE Jr, Powell DE, et al. Reversible hepatotoxicity associated with hepatic vitamin A accumulation in a protein-deficient patient. Gastroenterology 1982; 82:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/30\">",
"      Olson JA. Upper limits of vitamin A in infant formulas, with some comments on vitamin K. J Nutr 1989; 119:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/31\">",
"      Soprano DR, Soprano KJ. Retinoids as teratogens. Annu Rev Nutr 1995; 15:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/32\">",
"      Mahoney CP, Margolis MT, Knauss TA, Labbe RF. Chronic vitamin A intoxication in infants fed chicken liver. Pediatrics 1980; 65:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/33\">",
"      Lam HS, Chow CM, Poon WT, et al. Risk of vitamin A toxicity from candy-like chewable vitamin supplements for children. Pediatrics 2006; 118:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/34\">",
"      Cheruvattath R, Orrego M, Gautam M, et al. Vitamin A toxicity: when one a day doesn't keep the doctor away. Liver Transpl 2006; 12:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/35\">",
"      Penniston KL, Tanumihardjo SA. The acute and chronic toxic effects of vitamin A. Am J Clin Nutr 2006; 83:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/36\">",
"      Smith FR, Goodman DS. Vitamin A transport in human vitamin A toxicity. N Engl J Med 1976; 294:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/37\">",
"      Krasinski SD, Russell RM, Otradovec CL, et al. Relationship of vitamin A and vitamin E intake to fasting plasma retinol, retinol-binding protein, retinyl esters, carotene, alpha-tocopherol, and cholesterol among elderly people and young adults: increased plasma retinyl esters among vitamin A-supplement users. Am J Clin Nutr 1989; 49:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/38\">",
"      Graham-Maar RC, Schall JI, Stettler N, et al. Elevated vitamin A intake and serum retinol in preadolescent children with cystic fibrosis. Am J Clin Nutr 2006; 84:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/39\">",
"      Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA 2002; 287:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/40\">",
"      Micha&euml;lsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med 2003; 348:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/41\">",
"      Crandall C. Vitamin A intake and osteoporosis: a clinical review. J Womens Health (Larchmt) 2004; 13:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/42\">",
"      Rothman KJ, Moore LL, Singer MR, et al. Teratogenicity of high vitamin A intake. N Engl J Med 1995; 333:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/43\">",
"      Huiming Y, Chaomin W, Meng M. Vitamin A for treating measles in children. Cochrane Database Syst Rev 2005; :CD001479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/44\">",
"      Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs 1997; 53:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/45\">",
"      Chomienne C, Fenaux P, Degos L. Retinoid differentiation therapy in promyelocytic leukemia. FASEB J 1996; 10:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/46\">",
"      Leo MA, Lieber CS. Alcohol, vitamin A, and beta-carotene: adverse interactions, including hepatotoxicity and carcinogenicity. Am J Clin Nutr 1999; 69:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21736/abstract/47\">",
"      Feranchak AP, Gralla J, King R, et al. Comparison of indices of vitamin A status in children with chronic liver disease. Hepatology 2005; 42:782.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Nutrition American Academy of Pediatrics. Liver disease. In: Pediatric Nutrition Handbook, 6th ed, Kleinman, RE (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.959.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2571 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21736=[""].join("\n");
var outline_f21_14_21736=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHEMISTRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cellular differentiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Periodic distribution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - High-dose supplementation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Xerophthalmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EXCESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Acute toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chronic toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Adverse effects on bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Teratogenic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      THERAPEUTIC USES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Measles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Dermatology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Acute promyelocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      General population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2571\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2571|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/4/3136\" title=\"picture 1\">",
"      Bitots spot caused by vitamin A deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/45/19156\" title=\"picture 2\">",
"      Cornea vit A defic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2571|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/15/12541\" title=\"table 1\">",
"      Clinical symptoms of selected vitamin deficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/31/19967\" title=\"table 2\">",
"      Fat sol vit DRI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=related_link\">",
"      Cystic fibrosis: Nutritional issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=related_link\">",
"      Differentiation (retinoic acid) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=related_link\">",
"      Nutrient deficiencies in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6889?source=related_link\">",
"      Nutritional assessment in chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=related_link\">",
"      Overview of dietary trace minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=related_link\">",
"      Overview of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28871?source=related_link\">",
"      Overview of vitamin E",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22793?source=related_link\">",
"      Prevention and treatment of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34280?source=related_link\">",
"      The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_14_21737="Pacing system malfunction: Evaluation and management";
var content_f21_14_21737=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pacing system malfunction: Evaluation and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/14/21737/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21737/contributors\">",
"     David L Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/14/21737/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21737/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/14/21737/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21737/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/14/21737/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic evaluations of an implanted pacemaker are required to maintain optimal programming and to identify any system problem that should be corrected. Common pacing system problems of single and dual chamber pacemakers and the methods of evaluation and therapy will be reviewed here. The malfunctions discussed will be limited to those that are manifest on an ECG rhythm strip.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Complications not related to pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications not related to pacing are presented separately. These include infections, venous thrombosis and emboli, pacemaker syndrome, tricuspid regurgitation, and specific problems associated with dual-chamber pacemakers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=see_link\">",
"     \"Infections involving cardiac implantable electronic devices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link&amp;anchor=H11#H11\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Tricuspid regurgitation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31302?source=see_link\">",
"     \"Dual chamber pacing system malfunction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of pacing system malfunction is difficult to determine due to inconsistent definitions and the lack of any comprehensive reporting mechanism or registry [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21737/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of annual reports submitted to the FDA between 1990 and 2002 noted the following [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21737/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      8834 of 2.25 million pacemakers were explanted due to confirmed device malfunction (0.4 percent)",
"     </li>",
"     <li>",
"      From 1993 to 2002 the annual malfunction rate declined from 0.9 to 0.14 percent",
"     </li>",
"     <li>",
"      30 deaths were attributable to device malfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were reported in a meta-analysis of registries, including one from North America, one from the United Kingdom, and one from Denmark [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21737/abstract/2\">",
"     2",
"    </a>",
"    ]. The meta-analysis included data from 1982 to 2004 and over 475,000 pacemakers. A device was considered to have malfunctioned if there was a failure that required explantation. The annual rate of pacemaker failure fell from 1.2 percent in 1982 to 0.07 percent in 1998, after which the rate was relatively stable.",
"   </p>",
"   <p>",
"    Both of these reports included only those malfunctions serious enough to require explantation, and only include failures of the pacemaker itself, not the pacemaker leads.",
"   </p>",
"   <p>",
"    A more recent publication from a registry of implantable cardiac devices and leads that are removed from service for any reason over an eight-year period detailed the most common reasons for pacemaker failure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21737/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PACING SYSTEM COMPONENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pacing system is comprised of the pulse generator, also called the pacemaker, and the lead or leads which connect the pulse generator to the heart.",
"   </p>",
"   <p>",
"    The phrase \"pacing system malfunction\" includes problems that might arise from any of the components of the system. Inappropriately programmed pacemaker parameters, although they do not represent abnormal pacing system function, may be suboptimal for the patient. The normal characteristics and unique timing systems and algorithms of a given pacemaker are also an issue, as they may be interpreted as a malfunction by a clinician who is not familiar with the specific pulse generator. Recording system artifacts must always be considered in the differential diagnosis of a pacing system malfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PACING STIMULI PRESENT WITH LOSS OF CAPTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the principal requirements of a pacing system is that it prevents a heart rate that is slower than a predefined rate. This is accomplished by the release of an output pulse or stimulus from the pacemaker that is delivered to the myocardium via the pacing lead, inducing a depolarization of either the atrium or ventricle, depending upon the location of the lead. The failure of that stimulus to produce electrical activation of the heart and a subsequent cardiac contraction, is called",
"    <strong>",
"     noncapture",
"    </strong>",
"    or",
"    <strong>",
"     loss of capture",
"    </strong>",
"    . It is differentiated from capture by the absence of an evoked potential following the pacing stimulus. The diagnosis of loss of capture is based upon the presence of a stimulus, without a subsequent P wave or QRS complex, that occurs at a time when the myocardium is physiologically capable of being depolarized.",
"   </p>",
"   <p>",
"    One explanation for apparent loss of capture is failure to sense a native QRS complex followed by the release of the pacing stimulus at a time when the myocardium is physiologically refractory and incapable of being stimulated. While this may reflect a sensing malfunction, it is a normal phenomenon with regard to capture and should not be considered true capture malfunction. This is designated \"functional failure to capture\".",
"   </p>",
"   <p>",
"    To establish noncapture, it must be determined that a pacing stimulus was present on the ECG. Historically, on analog recording systems, unipolar stimuli were large and easily visible, and bipolar stimuli were diminutive and at times difficult to recognize. However, with current digital recording systems, this distinction is no longer reliable.",
"   </p>",
"   <p>",
"    If the output energy has been reduced, the stimulus may be virtually invisible on some ECG leads or may be eliminated entirely by high-frequency filters in the recording system. If no pacing stimuli are present in any of the available recording leads, then the problem is not loss of capture but a circuit interruption or oversensing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Causes of loss of capture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of loss of capture is relatively limited, and the likelihood of a given problem is highly correlated with the time since implantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Lead dislodgement or malposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common reason for loss of capture in the hours and days immediately following implantation is either lead dislodgement or malposition. This is manifested as a change in the morphology of the pacemaker-evoked depolarization when capture is present. A change in the anatomic position of the lead on a chest x-ray may also be seen. Identifying these problems is dependent upon comparison with a baseline (ie, when normal capture was present) 12-lead ECG and chest x-ray.",
"   </p>",
"   <p>",
"    Failure to sense native complexes as well as atrial or ventricular ectopy may also be associated with an unstable electrode within one of the cardiac chambers. If identified, treatment requires operative intervention to reposition the lead.",
"   </p>",
"   <p>",
"    Lead dislodgement does not prevent pacemaker output. If a magnet is applied to the pulse generator when the lead is dislodged, even though it may not result in cardiac depolarization, output stimuli will still occur at the magnet rate of the pulse generator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Inflammation and fibrosis at the electrode/myocardial interface",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inflammatory reaction and the resulting fibrous tissue that occur after implantation may act as an insulating shield around the electrode, effectively raising the threshold for stimulation and attenuating the amplitude and slew rate of the endocardial signal being sensed. This is a process termed \"lead maturation\". Although improvements in electrode design and materials have reduced the severity of this reaction, loss of capture will result if the capture threshold exceeds the programmed output of the pacemaker.",
"   </p>",
"   <p>",
"    High thresholds associated with lead maturation may be diagnosed by a stable morphology of the evoked complex when capture is present and a stable anatomic position on chest x-ray. The peak capture thresholds usually occur between several weeks to several months after implantation. Given sufficient time, the inflammatory reaction will subside, and the capture thresholds will improve.",
"   </p>",
"   <p>",
"    Management options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing the output of the pulse generator",
"     </li>",
"     <li>",
"      Lead repositioning",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Increase in capture threshold",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of capture may occur months to years after implantation due to one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A late rise in capture thresholds (ie, greater than four weeks post-implant) in the absence of dislodgment, thought to be secondary to excessive fibrosis at the",
"      <span class=\"nowrap\">",
"       lead/myocardial",
"      </span>",
"      interface, also called exit block.",
"     </li>",
"     <li>",
"      A primary cardiomyopathic process.",
"     </li>",
"     <li>",
"      The addition of various medications or the occurrence of a metabolic abnormality, both of which can transiently elevate the pacemaker capture and sensing thresholds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management is usually focused on correcting or eliminating the cause and, until this is accomplished, the output of the pacemaker is increased. When the etiology is a primary myocardial process, such as progressive fibrosis associated with a diffuse cardiomyopathy or a focal myocardial infarction, and the loss of capture cannot be managed by increasing the output of the pulse generator, an operative procedure will be required to place a new electrode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Low pacemaker output",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of capture may occur when the margin of safety for the programmed output with respect to the measured capture threshold is too low. While the capture threshold is a specific pulse amplitude at a given pulse duration, the measurement is made at only one point in time and usually with the patient in one position (supine or sitting). Capture thresholds may change during the day; with body position; and in association with various physiologic stresses, such as exercise, eating, and infection. Programming the output too close to the measured capture threshold may not provide a sufficient margin of safety, resulting in intermittent loss of capture. In this setting, the pacemaker, leads, and patient are all functioning normally, but the pulse generator is set inappropriately for the patient. Increasing the output will correct this problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lead failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrinsic lead failure may result in loss of capture. This is usually a late occurrence (ie, many years after implantation). One or more of the following mechanisms may be involved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deterioration of the lead insulation may allow a current leak, resulting in loss of capture.",
"     </li>",
"     <li>",
"      The generation of nonphysiologic electrical transients, causing oversensing or attenuation of the intrinsic cardiac electrogram, can lead to undersensing.",
"     </li>",
"     <li>",
"      Extrinsic stresses on the lead, such as between the first rib and clavicle subclavian crush injury, may result in a conductor fracture or insulation breach due to a point of stress on the lead. These leads must be replaced to reestablish normal pacing system function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A primary lead problem can often be identified by the measurement of lead impedance. This information can be obtained by telemetry of measured data. The normal range for lead impedances typically varies from 300 to 1500 ohms. An insulation failure will result in very low impedances, often less than 250 ohms, while an open circuit associated with a conductor fracture is commonly associated with very high impedances. Given the wide variability in impedance measurements between different lead models and even leads of the same model, changes in serial measurements are often more important than a single isolated assessment.",
"   </p>",
"   <p>",
"    Chest x-ray may help diagnose a fracture of the conductor coil. The lead insulation is radiolucent and a defect in the insulation will generally not be visible radiographically. Compression or distortion of the conductor coil may identify a point of increased external stress on the lead.",
"   </p>",
"   <p>",
"    In a bipolar coaxial lead, capture may be restored in the presence of an internal insulation failure or a fracture of the outer conductor coil by programming to the unipolar (tip to case) output configuration. However, this should be considered a temporary measure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Battery depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;All pacemakers require a power source to function. They are powered by a battery, which is usually comprised of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    &nbsp;iodine power cell. The longevity of these systems is often 6 to 8 years, but the longevity of any specific pulse generator depends upon the proportion of paced and sensed events, the programmed output and rate parameters, and the stimulation impedance.",
"   </p>",
"   <p>",
"    Each pacemaker incorporates one or more special features that will identify the recommended replacement time (RRT) or elective replacement indicator (ERI); a change in the magnet-induced rate and pacing mode is commonly seen. When this occurs, one can expect the system to function properly for another three months, allowing sufficient time to electively replace the pulse generator. If these indicators are ignored or the patient is lost to follow-up, the battery may deplete to a point where the effective output falls below the capture threshold, resulting in loss of capture.",
"   </p>",
"   <p>",
"    Battery depletion requires replacement of the pulse generator. If battery depletion occurs sooner than anticipated, based upon the programmed parameters of the pacemaker and the projections of the manufacturer, the integrity of the pacing lead should be carefully evaluated at the time of the replacement procedure. An insulation failure will result in a low-stimulation impedance that can accelerate battery depletion. Unless this is identified and the lead replaced, the new pulse generator will encounter a similar problem of rapid depletion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Recording system artifact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recording system artifacts may raise concerns about a system malfunction when they occur in a patient who has a pacemaker. Digital recording systems can either create a pacing stimulus in response to a high-frequency signal or initiate a blocking period in response to a very high-frequency signal to protect its own circuitry. This has the undesirable effect of either eliminating true pacing artifacts or creating a false artifact on the recording in response to a high-frequency transient of another etiology, mimicking either noncapture or undersensing.",
"   </p>",
"   <p>",
"    Another relatively common artifact occurs in systems that have special circuitry to protect the recorder from too large an incoming signal by blocking the circuit for a variable period of time. This may have the effect of showing the stimulus but eliminating the resultant evoked potential, leading to concerns about loss of capture. In this situation, there will be a visible T wave reflecting repolarization.",
"   </p>",
"   <p>",
"    Regardless of the cause, the likelihood of a recording system artifact is minimized by recording the rhythm in multiple simultaneous leads or sequentially in different leads.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PACING STIMULUS PRESENT WITH FAILURE TO SENSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second major functional capability of the modern pacemaker is the ability to sense or recognize intrinsic cardiac depolarizations. The pacemaker should be able to sense intrinsic atrial activity when the lead is located in the atrium, and intrinsic ventricular activity when the lead is located in the ventricle. Sensing is a complex phenomenon, being dependent upon the sense amplifier within the pacemaker and the size and characteristics of the signal inside the heart at the location of the pacing electrode. Although sensitivity is commonly reported as a function of the amplitude or size of the signal, it is a more complex process.",
"   </p>",
"   <p>",
"    Lack of sensing may occur with a QRS with very low amplitude. A signal with sufficient amplitude, but whose dominant frequencies fall outside the constraints imposed by the pacemaker's filters, will also not be sensed. Unless one is able to examine that portion of the signal from inside the heart that the pacemaker senses, which is termed the intrinsic deflection of the endocardial electrogram (EGM), it is not feasible to ascertain from the surface recording of either the isolated P wave or QRS complex why a specific signal is or is not sensed and where sensing occurs within the complex.",
"   </p>",
"   <p>",
"    To examine the intrinsic deflection as seen by the pacemaker, electrograms can either be recorded via the pacing lead at the time of implantation or be telemetered from the functioning pacemaker at any time postimplantation.",
"   </p>",
"   <p>",
"    The basic pacing interval associated with either single-chamber pacing or either channel of a dual-chamber system is divided into two subintervals.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediately following a paced or sensed event, the sense amplifier is rendered refractory. The purpose of the refractory period is to prevent the pacemaker from sensing and responding to known but inappropriate electrical or physiologic signals, such as ringing on the sense amplifier from the output pulse, the T wave, or far-field signals, such as R waves detected on the atrial channel, which are known to occur in close proximity to the paced or sensed event. However, appropriate signals that would normally be sensed at other times will not be sensed if they coincide with the refractory period. This becomes more common during dual-chamber pacing, and is also more likely to occur if the refractory period is programmed to a long interval.",
"      <br/>",
"      <br/>",
"      If there is a failure to sense or recognize a signal that should otherwise be sensed because the signal coincided with the refractory period, this is not a true system malfunction and should be termed \"functional undersensing\". Both true and functional undersensing are commonly associated with functional noncapture because the timing intervals are not reset, allowing the pacing stimulus to be delivered at a time when the myocardium is physiologically refractory.",
"     </li>",
"     <li>",
"      The other portion of the single-channel timing cycle is the alert period. An event occurring during the alert period should be sensed to trigger or inhibit the output of the pacemaker, depending upon the design of the system. The failure to sense an event in the alert period is true \"undersensing\".",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Causes of undersensing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of true undersensing include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Inadequate signal",
"    </span>",
"    &nbsp;&mdash;&nbsp;A signal is inadequate when it does not fulfill the pacemaker's requirements for an appropriate signal; there is too low an amplitude, slew rate, or inappropriate frequency content.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pacemaker programmed to a value insufficient to sense intrinsic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Undersensing occurs if the sensitivity parameter of the pacemaker is set inappropriately for the intrinsic signal characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Change in native signal",
"    </span>",
"    &nbsp;&mdash;&nbsp;A change in the native signal from the time of implant due to a primary myocardial process, such as an infarction, or transient changes as with drugs or metabolic abnormalities will cause undersensing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Ectopic beats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not uncommonly, ectopic beats that arise from a location different from that of the dominant intrinsic complex, whether atrial or ventricular, will not be sensed. Although a ventricular ectopic beat is frequently larger than the QRS on the surface ECG, the intracardiac electrogram, that is what is actually sensed, may be of very low amplitude.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Lead maturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inflammatory reaction associated with lead maturation may attenuate the amplitude and slew rate of the native complex by as much as 50 percent, so that if an original signal was only borderline in amplitude for appropriate sensing, undersensing may occur during this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Lead failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary lead malfunctions, most typically an insulation failure, will effectively attenuate the signal coming into the sense amplifier, resulting in undersensing problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Pulse generator failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be a true component malfunction involving the sense amplifier that results in undersensing. If this is the case, either the telemetered electrogram or the invasively recorded electrogram will be an appropriate signal for sensing, and other parameters of lead function will be normal. As a result, the pulse generator should be replaced and the leads reutilized.",
"   </p>",
"   <p>",
"    Although clinically important generator failure is uncommon, there has been a growing number of Food and Drug Administration (FDA) recalls and advisories because of potentially harmful consequences resulting from device malfunction. One study of FDA reports over a 10 year period found 52 advisories involving 408,500 pacemakers; these were primarily related to hardware malfunction or computer errors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21737/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increase in the number of advisories reflect a combination of factors, including a marked increase in the number of devices at jeopardy combined with improved surveillance techniques by the manufacturers. Virtually all the advisories were voluntarily initiated by the individual manufacturers; these were reported to the FDA at the same time as the clinical community was notified. The FDA has the authority to relabel the advisory as a recall. However, an advisory or a recall is not a guarantee that a problem will occur; rather these are usually issued when there is an increased incidence of a given problem about which the clinician should be made aware, at a minimum. The increased level of communication from the manufacturer to the clinical community facilitates the clinician's ability to care for the patient, although that same level of communication may increase the clinician's anxiety.",
"   </p>",
"   <p>",
"    Each of the manufacturers maintains a technical support group available at all times.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Environmental electrical fields",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pacemaker may detect and respond to strong electrical fields in the environment. There are very few sources of clinically significant electromagnetic interference found in the non-hospital environment. However, in the hospital a variety of diagnostic and therapeutic equipment, such as electrocautery, may interfere with normal pacing system function. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Electromagnetic interference'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/56/11142?source=see_link\">",
"     \"Cardiac device interactions with electromagnetic fields\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Magnet application",
"    </span>",
"    &nbsp;&mdash;&nbsp;During magnet application, a reed switch closes within the pacemaker, thereby bypassing the sense amplifier and inducing asynchronous function. Magnet application is essential to confirm the integrity of the output circuit when the pacemaker is otherwise being inhibited. A change in the magnet-induced behavior, usually rate but sometimes AV delay and mode, is also used by many manufacturers as an indicator of battery depletion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the magnet behavior is unique and different from the programmed rates and intervals, it is relatively easy to identify the expected loss of sensing due to magnet application.",
"     </li>",
"     <li>",
"      If the magnet application results in rates and intervals that are identical to the programmed parameters of the pacemaker, even though in an asynchronous manner, and the individual interpreting the ECG is not informed that a magnet was placed over the pulse generator, there will probably be concern about loss of sensing as indicative of a true malfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Noise detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The noise mode response is another situation in which asynchronous behavior is consistent with normal system behavior. Electrical noise is defined by the pulse generator as a series of electrical signals occurring at a very rapid rate, frequently greater than 6 Hz or 360 cycles or signals per minute. This is above the physiologic range for heart rate, and if the pacemaker \"sees\" signals coming in this rapidly, it interprets these as not being true physiologic signals. Rather than inhibit the output in response to these signals, which leaves the patient at potential jeopardy from asystole, most systems are designed to function in an asynchronous manner as long as electrical noise is being detected.",
"   </p>",
"   <p>",
"    Noise detection typically occurs during the terminal portion of the refractory period. The beginning of the refractory period is the equivalent of the effective refractory period in the heart; at this time, there is absolutely no sensing. The last portion of the refractory period is the noise sampling period (NSP), which would be the equivalent of the functional refractory period. If an event is sensed during the NSP, another, and often shorter, refractory period is initiated. It is also comprised of an absolute refractory period and an NSP. If a signal is sensed in this next NSP, the refractory period is again reset.",
"   </p>",
"   <p>",
"    Assuming this continues to occur, the basic rate timing will complete and, since nothing that the pacemaker recognized as a true or appropriate signal occurred, a pacemaker pulse will be released. If the patient's native rhythm is asystole and the system is detecting electrical noise, pacing will be maintained and the patient will be protected. If, on the other hand, the patient has an intrinsic rhythm, the noise mode response will result in asynchronous pacing, with potential competition between the pacemaker and native rhythm appearing as \"undersensing\" on the ECG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Management of undersensing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pacemakers have the capability for electrogram telemetry with a broad band-pass filter, which provides an excellent means to evaluate the characteristics of the native signals to determine why they are not being sensed. Alternatively, management may involve an empiric increase of the sensitivity of the pacemaker, which makes it responsive to progressively smaller amplitude signals. This may be counterproductive, since the more responsive the pacemaker is to smaller signals, the more likely it is to sense inappropriate outside signals, such as electrical potentials arising from either the skeletal muscle contiguous to the pulse generator with unipolar sensing systems or that associated with diaphragmatic contractions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ELECTROMAGNETIC INTERFERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical noise is a series of rapid electrical signals that, when sensed by the pacemaker, causes the pacemaker to function in an asynchronous manner, suggesting undersensing. This is intended to avoid asystole since the pacemaker can no longer differentiate a true physiologic signal that would appropriately inhibit the system from a false signal that should be ignored. While household and work-based electrical equipment inhibited the early generation of pacemakers, improvements in circuit design have virtually eliminated these causes of electromagnetic interference (EMI).",
"   </p>",
"   <p>",
"    Strong electrical fields applied either in very close proximity or directly to the patient are required for there to be a major effect on the implanted pacing system. This most commonly occurs in the medical environment, when the implanted system is exposed to electrocautery at the time of surgery, internal or external cardioversion or defibrillation, and magnetic resonance imaging (",
"    <a class=\"graphic graphic_table graphicRef51277 \" href=\"UTD.htm?25/15/25852\">",
"     table 1",
"    </a>",
"    ). Other causes of EMI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/56/11142?source=see_link\">",
"     \"Cardiac device interactions with electromagnetic fields\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Therapeutic radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic radiation can have adverse effects on pacemakers. Radiation generating equipment produces strong electromagnetic fields that can temporarily alter pacemaker function in a variety of ways. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Magnetic resonance imaging'",
"    </a>",
"    below.) Early devices called betatrons generated much stronger magnetic fields than modern linear accelerators, but both devices are capable of causing disruption of pacemaker operation.",
"   </p>",
"   <p>",
"    The ionizing radiation may result in electrical reset of a device or can permanently damage the pacemaker by causing defects in semiconductor insulation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21737/abstract/5\">",
"     5",
"    </a>",
"    ]. Clinical manifestations may include sudden no-output of the pacemaker or runaway pacemaker.",
"   </p>",
"   <p>",
"    The following recommendations for the management of patients with pacemakers undergoing radiation therapy are adopted from guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21737/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have the patient's pacemaker status evaluated by someone with pacemaker expertise before and soon after completion of therapy.",
"     </li>",
"     <li>",
"      Before treatment, estimate and record the dose (from scatter) to be received by the pacemaker.",
"     </li>",
"     <li>",
"      Always keep the pacemaker outside the radiation beam.",
"     </li>",
"     <li>",
"      The pulse generator should be moved if it lies within the therapeutic field. This should be done before radiation therapy is scheduled to begin, allowing the wound time to fully heal.",
"     </li>",
"     <li>",
"      Carefully observe the patient during the first therapy session to verify that no transient malfunctions are occurring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Therapeutic electrical current",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which electrocautery, cardioversion, and defibrillation, all of which deliver a large amount of energy to the body, can damage the implanted pacing system is virtually identical.",
"   </p>",
"   <p>",
"    In a unipolar pacing system, the case of the pulse generator, which is an active part of the circuit, can acquire the energy and subsequently deliver it to the circuitry. On occasion, this has either damaged the circuitry or, more frequently, reprogrammed the pacemaker.",
"   </p>",
"   <p>",
"    Manufacturers have incorporated a variety of circuits, most commonly employing Zener diodes, designed to protect the complex electronics of the pacemaker from a voltage surge of 12 V or greater. These circuits shunt the energy acquired by the housing of the pulse generator to the lead, which results in a large amount of energy being delivered to the heart via the electrode. The energy concentrated at the electrode-myocardial interface has induced endocardial burns, causing an elevation of the capture and sensing threshold.",
"   </p>",
"   <p>",
"    In addition, sustained electrical signals associated with electrocautery may induce ventricular fibrillation in the electrically unstable patient; this occurs in a manner analogous to the intentional induction of ventricular fibrillation for defibrillation threshold testing at the time of implantable cardioverter-defibrillator (ICD) insertion.",
"   </p>",
"   <p>",
"    Energy can also enter the pacing system directly through the leads by a process known as capacitive coupling. Thus, even bipolar pacing systems are not immune to adverse effects from electrocautery or defibrillation.",
"   </p>",
"   <p>",
"    Lower doses of electrical current that may not cause damage to the pacing system may nonetheless cause transient pacemaker malfunction. The pacemaker may sense the externally applied electrical field, causing inappropriate inhibition of pacing, or in a DDD pacemaker, the electrical field could be sensed on the atrial sensing circuit with 'tracking' of the noise by the ventricular channel to result in inappropriately rapid ventricular pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     External cardioversion/defibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When external cardioversion or defibrillation is performed, the paddles should be as far from the pulse generator as possible without compromising the efficacy of the procedure. Where feasible, the current path should be perpendicular to the plane of the pacing system; this would usually mean using anterior-posterior paddles as with R2 pads.",
"   </p>",
"   <p>",
"    With appropriate positioning of the paddle or pads, cardioversion or defibrillation can be safely performed with minimal risk to the implanted device. This was illustrated in a series of 44 patients with implanted devices, including pacemakers and ICDs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21737/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients were randomly assigned to either monophasic or biphasic shocks. Cardioversion paddles were placed in an anterior-posterior position, at least 8 cm from the device. Serial device interrogations demonstrated small changes in pacing impedances and ventricular sensing immediately after cardioversion that returned to baseline within one week. There were no differences between the effects of monophasic or biphasic shocks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Electrocautery",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the patient undergoes surgery requiring electrocautery, the use of bipolar cautery will minimize the electrical field affecting the pacing system. At a minimum, every effort should be made to assure that the current path for the electrocautery will not encompass the pacing system.",
"   </p>",
"   <p>",
"    In the pacemaker-dependent patient, programming the system to an asynchronous mode (VOO or DOO) at the beginning of the procedure has been recommended. Alternatively, a magnet placed over the pacemaker will disable all sensing, producing a VOO or DOO mode. The asynchronous mode will prevent the pacemaker from being inhibited, which may result in a significant bradycardia or asystole in these patients. If the pacemaker is reprogrammed for a surgical procedure, the clinician or appropriately trained support staff should be available to restore usual programmed parameters following the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been significant debate about whether a patient with an implanted pacemaker should be allowed to undergo a magnetic resonance imaging (MRI) study. The risks of scanning patients with permanent pacemakers or ICDs are related to possible movement of the device, programming changes, asynchronous pacing, activation of tachyarrhythmia therapies, inhibition of pacing output, and induced currents in lead wires leading to heating",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac stimulation. Despite reports that some patients with pacemakers or ICDs have been scanned safely, the presence of a pacemaker or ICD is still considered a strong relative contraindication to routine MR examination. This subject is discussed in detail elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most patients with implanted cardiac devices can undergo CT scans without any adverse consequences, direct exposure to high x-ray dose rates during CT examinations can potentially cause transient changes in pacemaker output pulse rate [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21737/abstract/8\">",
"     8",
"    </a>",
"    ]. However, at this time, the evidence for device interference by computed tomography is very limited and should rarely, if ever, limit device patients from undergoing a CT scan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11481289\">",
"    <span class=\"h2\">",
"     Extracorporeal shock wave lithotripsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal shock wave lithotripsy is occasionally performed as a treatment for upper urinary tract calculi. An older concern was that in patients with pacemakers or ICDs that incorporate a piezoelectric crystal for rate-adaptive pacing, the piezoelectric crystal can be shattered by the shock wave. Therefore, if such a sensor is incorporated in a device placed in the abdomen, extracorporeal shock wave lithotripsy is probably best avoided. However, there are now very few devices that incorporate a piezoelectric crystal.",
"   </p>",
"   <p>",
"    There have also been concerns that extracorporeal shock wave lithotripsy may cause significant mechanical forces that can shatter piezoelectric elements, circuitry, or lead connections but this is less well established. For patients who have any significant degree of pacemaker dependence, pacing mode should be reprogrammed to VOO or DOO because of the potential for inhibition of the ventricular pacing circuit due to interference from extracorporeal shock wave lithotripsy. However, in patients with an ICD, one study found that lithotripsy can be performed safely in those with tiered-therapy ICDs; however, it is recommended that antitachycardia therapies be turned \"off\" and the patient continuously monitored electrocardiographically during the procedure. Following the procedure the device should be interrogated, antitachycardia therapies turned back 'on' and confirmation that final programming matches the programmed values prior to the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21737/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27079?source=see_link\">",
"     \"Management of ureteral calculi\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     PACING STIMULI ABSENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absence of pacing stimuli is certainly appropriate when there is an intact native rhythm. However, in the patient who has a pacemaker, one should usually not observe an absence of pacing stimuli with pauses in the rhythm that are longer than the programmed base rate of the pacemaker. If these pauses occur in the presence of pacing stimuli that do not capture, this is a noncapture problem. If there are no visible pacing stimuli, then one of three possible system malfunctions have occurred:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The malfunction may arise from oversensing by the pacemaker of an inappropriate signal that is not visible on the surface ECG.",
"     </li>",
"     <li>",
"      Failure to deliver a pacing stimuli at the appropriate time may result from an open circuit, which may be due to inadequate lead fixation to pacemaker generator at the time of implantation (loose set screw), air in the pocket of a pacemaker programmed to unipolar pacing configuration, or lead fracture.",
"     </li>",
"     <li>",
"      A component in the pulse generator may have failed. This is exceedingly rare, and other possibilities should be considered first.",
"     </li>",
"     <li>",
"      Hysteresis could result in an initial interval from an intrinsic event to the paced event being longer than the programmed base rate. Confusion may arise if it is not recognized that hysteresis is programmed \"on\".",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Applying a magnet over the pacemaker will usually allow one to quickly differentiate an oversensing problem from an open circuit or pulse generator component malfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If pacing resumes with a stimulus being present, whether or not there is intact capture, the etiology of the absent pulses is likely oversensing. In unipolar pacing systems, particularly when programmed to a very sensitive setting, oversensing of myopotentials may be more likely to occur.",
"     </li>",
"     <li>",
"      If magnet application fails to eliminate the pauses, the problem is not one of oversensing, but is either a component failure within the pulse generator, an open circuit, or, in the setting of a bipolar coaxial lead, an internal insulation failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Oversensing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oversensing is somewhat more common in the unipolar sensing configuration because the antenna for signal detection is much larger, extending from the housing of the pulse generator to the electrode located within the heart. Bipolar systems, in which both active electrodes are inside the heart, have a much smaller antenna effect and a better",
"    <span class=\"nowrap\">",
"     signal/noise",
"    </span>",
"    ratio with respect to electrical noise originating from outside the heart. As a result, bipolar systems can often be programmed to very sensitive settings without encountering oversensing.",
"   </p>",
"   <p>",
"    Although more resistant to oversensing, bipolar leads do not totally eliminate this problem. Internal insulation failure in bipolar coaxial leads has produced repeated make-break contacts between the two conductor coils. Large nonphysiologic electrical transients result, which can be seen by the pacing system and inhibit it, but are not visible on the surface ECG. When this occurs, reducing the sensitivity will probably not correct the system malfunction, and management will require replacement of the malfunctioning pacing lead.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oversensing can usually be corrected by reducing the pacemaker sensitivity, ie, programming the pacemaker to a higher sensitivity number that defines the smallest millivolt amplitude of the signal that the pacemaker can sense. Reducing the sensitivity predisposes to episodes of undersensing if the amplitude of the intrinsic signal is too small, a common problem with atrial sensing. In this case, programming the pacemaker to the triggered mode will result in periods of an accelerated irregular paced rhythm during periods of oversensing, but the patient will be protected from asystole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Open circuit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of pauses due to an open circuit is a conductor fracture. This usually occurs at a point of stress, only becoming manifest months to years post implant. If pauses are recognized in the early post implant period, they are likely due to an inadequately tightened set screw that secures the lead to the pulse generator connector block.",
"   </p>",
"   <p>",
"    A chest x-ray may allow identification of either the location of the conductor fracture or a lead partially pulled out of the connector block, in which case the tip of the terminal pin does not extend through the set screw of the connector block. If either a loose set screw or a conductor fracture is identified, an operative procedure will be required to correct the problem by either replacing the lead or tightening the set screw.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Short circuit due to insulation breakdown",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another potential etiology for failure to output is a breach of the internal insulation in a bipolar coaxial lead. This occurs when both conductors are making intimate contact, allowing the current traveling down the distal conductor to short-circuit to the proximal conductor before it ever reaches the electrodes within the heart. Without any current or only minimal current reaching the heart, the effective output pulse will be subthreshold and invisible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Lead impedance measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead impedance measurements, either invasively or via telemetry, will readily differentiate a conductor fracture (very high impedances) from an insulation defect (very low impedances).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the case of a loss of insulation integrity, programming the output configuration to unipolar may restore capture. Part of the current flow down the distal conductor is shunted to the proximal conductor when it reaches the short circuit. If the insulation abnormality is in the outer portion of a bipolar lead, programming to a unipolar configuration excludes the abnormality and current flows between the inner electrode and the pulse generator 'can.' Restoration of capture may convert a potential emergency to a problem that can be managed electively. However, reestablishment of pacing using the programmable capability of the pacemaker is not a permanent solution and the malfunctioning lead should be replaced when clinically appropriate.",
"   </p>",
"   <p>",
"    Programming the output configuration to unipolar, however, will not eliminate the oversensing problem discussed earlier.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Hysteresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysteresis is a feature that can be misinterpreted as a pacing system problem when pacing stimuli are absent.",
"   </p>",
"   <p>",
"    In a pacemaker programmed with hysteresis, the escape interval of the pacemaker is significantly longer than the rate at which it will pace, and thus the escape pacing rate is slower than the automatic basic pacing interval. It is commonly reported as either a ratio of rates, ie,",
"    <span class=\"nowrap\">",
"     70/50,",
"    </span>",
"    which means that the basic rate is 70 bpm but the rate at which the pacemaker will escape to release the first pacing pulse is 50 bpm, or a millisecond addition to the basic pacing interval, ie, 300 msec, which means that the escape interval before the pacing will begin is 300 msec longer than the basic pacing interval.",
"   </p>",
"   <p>",
"    The original goal of hysteresis was to allow the patient who only intermittently and infrequently required pacing support to remain in a normal native rhythm at lower rates when pacing was not required. When AV block developed such that pacing was required, sustained pacing at a very slow rate would be hemodynamically compromising. At these times, hysteresis would allow for the faster paced ventricular rate required.",
"   </p>",
"   <p>",
"    The key to suspecting hysteresis is that the pacemaker is either still inhibited when native heart rates are lower than the programmed base rate, or when pauses occur, they only occur following a native sensed beat. Hysteresis is a programmable parameter in many pacemakers, and, if it is not desired, it can be turned off by programming. Hysteresis does not reflect a malfunction of either the pulse generator or the lead.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Recording system artifact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recording system artifacts can also mimic no-output situations. Recording lead disconnections are a fairly common example of such an artifact. They will usually be characterized by an abrupt termination or initiation of a complex in the middle of another complex plus simultaneous failure of the native rhythm coincident with the paced rhythm. Thus, not only does the pacing system appear to fail, but the baseline becomes isoelectric and the patient's sinus mechanism or atrial fibrillation also disappears.",
"   </p>",
"   <p>",
"    Another recording system artifact is an isoelectric native complex, which, although appropriately sensed by the pacemaker causing inhibition, is not seen in the specific lead that is being monitored, resulting in the appearance of excessively long pauses. This requires a high index of suspicion to recognize. Confirmation requires additional recordings using either different leads or multiple simultaneous leads.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     RECORDING SYSTEM ARTIFACTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many recording system artifacts have already been discussed in the preceding sections, but there are other recording system artifacts that are confusing in single-chamber systems and can render dual-chamber recordings virtually impossible to interpret.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Variable recording speed",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic recording system problem is a variable or unexpected chart speed. This is a particularly difficult problem with rate-modulated rhythms and pacemakers, which are capable of tracking physiologic and pathologic intrinsic atrial rhythms. If the rhythm strip was thought to have been recorded at 25",
"    <span class=\"nowrap\">",
"     mm/second",
"    </span>",
"    but was really recorded at 50",
"    <span class=\"nowrap\">",
"     mm/second,",
"    </span>",
"    the effective rate would be one-half its actual rate. This might be interpreted as battery depletion if one did not pay attention to the simultaneous excessive increase in QRS and QT intervals.",
"   </p>",
"   <p>",
"    Fluctuating recording speeds may occur in Holter recorders with a partially depleted battery. This can also be recognized by the concomitant changes in the PR, QRS, and QT intervals of the native complexes and AV, QRS, and QT intervals of the paced complexes. Once recognized, further attempts to interpret the function of the pacing system should cease, and the study should be repeated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Amplitude of pacing stimulus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amplitude of the pacing stimulus may provide a wealth of information, but only when recorded with an analog ECG machine. In a stable recording lead, changes in the amplitude of the pacing stimulus commonly reflect varying levels of delivered energy and polarity configuration. It must be stressed that this",
"    <strong>",
"     is only the case with analog recording systems",
"    </strong>",
"    and analog recording systems are now infrequently used.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The stimulus amplitude will decrease in a partially open circuit, which attenuates the current flow.",
"     </li>",
"     <li>",
"      An insulation defect in a unipolar lead will short-circuit the system, resulting in a decrease in the stimulus amplitude.",
"     </li>",
"     <li>",
"      An insulation defect developing between the proximal conductor and the tissue in a bipolar system will result in a larger stimulus, making it look more like a unipolar system.",
"     </li>",
"     <li>",
"      Beat-to-beat fluctuations in the stimulus raise concerns about a pacing system problem, with special attention directed to the lead.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contemporary ECG recording systems use digital technology, allowing for computer interpretations of the recorded rhythms and 12-lead ECGs. In these systems, the signals are digitized for data storage and processing. The digitizing system in most ECG recording systems samples the electrical activity of the signal 250 times a second or every 4 msec. With the standard pacing pulse being only 0.4 to 0.6 msec in duration, the sampling rate of the standard digital ECG machine may miss the pulse entirely or detect a relatively large deflection associated with the primary pulse or a very small deflection of opposite polarity, which is the recharge pulse. A wide variety of complexes representing the pacing stimulus from a large deflection in one direction to a small deflection in the opposite direction and anything in between might be seen on the digital recording, all of which would be normal. The potential information that is available from an analog recording will be lost with most digital recordings, and the resulting variation in the pacing stimulus amplitude and polarity should not be misinterpreted as indicative of a malfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     PACING SYSTEM EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the system involves a single-chamber or dual-chamber pacemaker, the evaluation is similar. Interrogation of the pacemaker can be performed in the office or hospital, or using remote monitoring when the pacemaker has remote capability [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21737/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. As an example of the effectiveness of remote monitoring, among 538 patients randomly assigned to remote monitoring or standard office-based monitoring, there was no significant difference in adverse events or complications, but remote monitoring resulted in 56 percent fewer ambulatory office visits [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21737/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Establish programmed parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interrogate the pacemaker so that the programmed parameters are known. In those systems that provide measured data regarding lead and battery function, obtain this information as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Evaluate capture",
"    </span>",
"    &nbsp;&mdash;&nbsp;To evaluate capture, the ECG is examined to determine if pacing stimuli are visible. Most contemporary pacemakers have automatic pacing threshold testing algorithms. The following points may be helpful when there is difficulty interpreting the auto-threshold tracings or when capture thresholds are determined manually.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the native rate is faster than the paced rate, thereby inhibiting the system, the rate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      AV interval should be reprogrammed so that stimuli are visible.",
"     </li>",
"     <li>",
"      Capture is intact if there is a distinct change in the morphology of the QRS or P wave that follows each stimulus and if this morphology is stable and different from the native complexes. If this is not seen, there is noncapture, and the etiologies discussed above should be considered.",
"     </li>",
"     <li>",
"      If initial evaluation shows a pacing stimulus that is simultaneous with the native QRS complex, changing the rate and AV intervals will be helpful.",
"     </li>",
"     <li>",
"      It may be necessary to assess the capture threshold by adjusting the output and demonstrating loss of capture before it is certain that capture was intact on the initial tracings. If there is loss of capture, it must be established if this is a functional loss of capture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Evaluate sensing",
"    </span>",
"    &nbsp;&mdash;&nbsp;To evaluate sensing, intrinsic complexes must be present. Most contemporary pacemakers have automatic pacing threshold testing algorithms. Similar to capture determination, the following points may be helpful when there is difficulty interpreting the automatic sensing determination or when sensing thresholds are determined manually.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the rhythm is totally paced, the rate can be decreased, the AV delay increased, or the unit programmed to a nontracking mode in order to evaluate ventricular sensing.",
"     </li>",
"     <li>",
"      If the system is then inhibited and the native rhythm appears, sensing is intact.",
"     </li>",
"     <li>",
"      To evaluate atrial sensing, it may be necessary to reduce the base pacing rate and shorten the AV interval. This will result in P wave tracking in the presence of intact atrial sensing. If sensing is not present or consistent, the etiology should be evaluated and appropriate corrective actions taken.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h1\">",
"     PACEMAKER DIAGNOSTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to interrogation of programmed and measured data, which is absolutely essential, most systems can provide telemeter event markers and endocardial electrograms. When these are available, the clinician should take advantage of them, since they will greatly facilitate the evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Event markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Event markers are indicators of pacing and sensing reported directly by the pacemaker. However, the fact that the pacemaker released an output pulse does not mean that the pacing stimulus effectively captured the heart muscle to cause a depolarization. In addition, the fact that the system reports that it sensed an event does not mean that this was an appropriate complex to be sensed. Thus, the event markers need to be correlated with the surface ECG recordings",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intracardiac electrogram, and are most valuable when the event markers are printed along with a simultaneously recorded surface ECG or intracardiac electrogram.",
"   </p>",
"   <p>",
"    A sense marker coinciding with a native P or R wave confirms proper sensing, unless there is a P marker over a native R wave or vice versa, in which case there may be a problem such as a dislodged atrial lead, inappropriate connection of the atrial and ventricular leads into the pulse generator, or far-field sensing. If the event markers indicated that the pacemaker is sensing an event that is not visible on the surface ECG, further evaluation is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Electrogram assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocardial electrograms can be particularly helpful in examining the morphology of the native complexes to determine capture as well as why a given signal may not have been sensed. It is also useful in examining the signals that are being sensed when these are not readily identified from the surface ECG. Electrogram telemetry will greatly facilitate the evaluation, allowing it to be completed more expeditiously and provide information that may not be easily acquired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h1\">",
"     LEAD EXTRACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pacemaker leads may need to be removed from time to time, most often for infection or mechanical lead failure. Lead extraction should be performed by someone trained in the technique. Although complications are lower when laser or electrocautery techniques are utilized, there are inherent potential complications and these should be discussed with the patient prior to the procedure.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link&amp;anchor=H10#H10\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Lead removal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the sophistication and complexity of contemporary pacemakers, appropriate evaluation may require a significant amount of time. It is imperative to perform a careful evaluation of the entire system with review of all stored data without presupposing that the superficial appearance of \"normal\" function truly reflects normal pacing system function.",
"   </p>",
"   <p>",
"    The pacemaker cannot unpredictably alter its manner of function unless there is a component malfunction. Given the overall reliability of the pulse generators, if a bizarre behavior is encountered, one should consider either some eccentricity of the specific pulse generator, a lead problem, or a recording artifact before entertaining the diagnosis of a pulse generator failure.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21737/abstract/1\">",
"      Maisel WH, Moynahan M, Zuckerman BD, et al. Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA 2006; 295:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21737/abstract/2\">",
"      Maisel WH. Pacemaker and ICD generator reliability: meta-analysis of device registries. JAMA 2006; 295:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21737/abstract/3\">",
"      Hauser RG, Hayes DL, Kallinen LM, et al. Clinical experience with pacemaker pulse generators and transvenous leads: an 8-year prospective multicenter study. Heart Rhythm 2007; 4:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21737/abstract/4\">",
"      Maisel WH, Sweeney MO, Stevenson WG, et al. Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators. JAMA 2001; 286:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21737/abstract/5\">",
"      Solan AN, Solan MJ, Bednarz G, Goodkin MB. Treatment of patients with cardiac pacemakers and implantable cardioverter-defibrillators during radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21737/abstract/6\">",
"      Marbach JR, Sontag MR, Van Dyk J, Wolbarst AB. Management of radiation oncology patients with implanted cardiac pacemakers: report of AAPM Task Group No. 34. American Association of Physicists in Medicine. Med Phys 1994; 21:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21737/abstract/7\">",
"      Manegold JC, Israel CW, Ehrlich JR, et al. External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator systems: a randomized comparison of monophasic and biphasic shock energy application. Eur Heart J 2007; 28:1731.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/medwatch/safety/2008/safety08.htm#ElectronicMedical (Accessed on June 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21737/abstract/9\">",
"      Chung MK, Streem SB, Ching E, et al. Effects of extracorporeal shock wave lithotripsy on tiered therapy implantable cardioverter defibrillators. Pacing Clin Electrophysiol 1999; 22:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21737/abstract/10\">",
"      Mabo P, Victor F, Bazin P, et al. A randomized trial of long-term remote monitoring of pacemaker recipients (the COMPAS trial). Eur Heart J 2012; 33:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21737/abstract/11\">",
"      Dubner S, Auricchio A, Steinberg JS, et al. ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). Europace 2012; 14:278.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1013 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21737=[""].join("\n");
var outline_f21_14_21737=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H54\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Complications not related to pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PACING SYSTEM COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PACING STIMULI PRESENT WITH LOSS OF CAPTURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Causes of loss of capture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Lead dislodgement or malposition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Inflammation and fibrosis at the electrode/myocardial interface",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Increase in capture threshold",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Low pacemaker output",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lead failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Battery depletion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Recording system artifact",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PACING STIMULUS PRESENT WITH FAILURE TO SENSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Causes of undersensing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Inadequate signal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pacemaker programmed to a value insufficient to sense intrinsic activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Change in native signal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Ectopic beats",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Lead maturation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Lead failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Pulse generator failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Environmental electrical fields",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Magnet application",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Noise detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Management of undersensing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ELECTROMAGNETIC INTERFERENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Therapeutic radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Therapeutic electrical current",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - External cardioversion/defibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Electrocautery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11481289\">",
"      Extracorporeal shock wave lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      PACING STIMULI ABSENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Oversensing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Open circuit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Short circuit due to insulation breakdown",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Lead impedance measurements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Hysteresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Recording system artifact",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      RECORDING SYSTEM ARTIFACTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Variable recording speed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Amplitude of pacing stimulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      PACING SYSTEM EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Establish programmed parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Evaluate capture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Evaluate sensing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      PACEMAKER DIAGNOSTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Event markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Electrogram assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      LEAD EXTRACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1013\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1013|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/15/25852\" title=\"table 1\">",
"      EMI with cardiac devices",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/56/11142?source=related_link\">",
"      Cardiac device interactions with electromagnetic fields",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31302?source=related_link\">",
"      Dual chamber pacing system malfunction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=related_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27079?source=related_link\">",
"      Management of ureteral calculi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_14_21738="Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)";
var content_f21_14_21738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/14/21738/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21738/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/14/21738/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21738/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21738/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/14/21738/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/14/21738/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/14/21738/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Classic\" granulomatosis with polyangiitis (Wegener's) is a form of systemic vasculitis (polyangiitis) with necrotizing granulomatous inflammation of the upper and lower respiratory tracts, systemic necrotizing vasculitis, and necrotizing glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A \"limited\" form, with clinical findings isolated to the upper respiratory tract or the lungs, occurs in approximately one-fourth of cases. The designation &ldquo;limited&rdquo; is mostly used as a separator from &ldquo;severe&rdquo; disease for treatment stratification and does not include isolated ANCA-associated diffuse alveolar hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/3\">",
"     3",
"    </a>",
"    ]. Many patients with &ldquo;limited&rdquo; disease subsequently develop systemic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Boards of Directors of the American College of Rheumatology (ACR), American Society of Nephrology (ASN), and the European League Against Rheumatism (EULAR) have recommended that the name Wegener&rsquo;s granulomatosis be changed to granulomatosis with polyangiitis (Wegener&rsquo;s), abbreviated as GPA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H182265351#H182265351\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'New terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other organ systems that may be involved in GPA include [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Joints (myalgias, arthralgias, arthritis)",
"     </li>",
"     <li>",
"      Eyes (conjunctivitis, episcleritis, uveitis)",
"     </li>",
"     <li>",
"      Skin (vesicular, purpuric, and hemorrhagic lesions, subcutaneous nodules)",
"     </li>",
"     <li>",
"      Nervous system (mononeuritis multiplex, cranial nerve abnormalities, external ophthalmoplegia, tinnitus, hearing loss)",
"     </li>",
"     <li>",
"      Heart (pericarditis, myocarditis, conduction system abnormalities)",
"     </li>",
"     <li>",
"      Less commonly, the gastrointestinal tract, lower genitourinary tract (including the prostate or ureter), parotid glands, thyroid, liver, or breast",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major features related to respiratory tract involvement in GPA will be reviewed here. Issues related to the pathogenesis, clinical manifestations, diagnosis, therapy, and outcomes in GPA and the related disorder microscopic polyangiitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=see_link\">",
"     \"Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24824?source=see_link\">",
"     \"Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175807358\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic findings in granulomatosis with polyangiitis (GPA) vary with the location and type of involvement in the respiratory tract and elsewhere. The histopathology of renal GPA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H377577#H377577\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Histopathologic classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175807366\">",
"    <span class=\"h2\">",
"     Chronic rhinosinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic examination of nasal and sinus tissue involved by GPA typically reveals extensive tissue necrosis and infiltration with a mixed population of inflammatory cells; necrotizing granulomas are occasionally present. Direct evidence of vasculitis is rarely seen in pathologic specimens from the upper respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4204045\">",
"    <span class=\"h2\">",
"     Tracheobronchial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheobronchial GPA disease includes subglottic and lower tracheal and bronchial stenoses, tracheal and endobronchial mass lesions, and less commonly tracheobronchial malacia, follicular bronchiolitis, and bronchiolitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The histopathologic findings of the various forms of bronchiolitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link&amp;anchor=H5#H5\">",
"     \"Bronchiolitis in adults\", section on 'Pathologic classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial lesion in tracheal and bronchial stenosis appears to be a circumferential area of friable mucosa and ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/10\">",
"     10",
"    </a>",
"    ]. Fibrotic scarring may occur during the resolution phase, and result in stenosis or, less commonly, tracheomalacia, or bronchiectasis. Biopsies of areas of airway stenosis due to GPA often reveal nonspecific inflammation typical of granulation tissue or fibrotic scarring, but rarely show vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/10,12\">",
"     10,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsies of tracheal and bronchial masses often show fibrinoid necrosis, microabscesses, and infiltration by epithelioid histiocytes and neutrophils without clear vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4204099\">",
"    <span class=\"h2\">",
"     Pulmonary parenchymal nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic lung parenchymal lesions of GPA are firm, hemorrhagic to yellow-gray spherical nodules, ranging in size from 0.3 to 12 cm with an average size of 2.4 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/14\">",
"     14",
"    </a>",
"    ]. Central necrosis, more friable than caseous, may be present, resulting in cavities in 25 to 50 percent of nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Microscopically, transmural infiltration of blood vessels with inflammatory cells is noted, associated with granulomatous inflammation in the surrounding tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/15\">",
"     15",
"    </a>",
"    ]. GPA is categorized as a small vessel vasculitis, but may affect arteries, arterioles, capillaries, venules, and veins. Necrosis of the vessel walls",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    necrosis of inflammatory cells within the vessel walls may be visible. One issue in the histopathologic diagnosis of GPA is that infections (typically granulomatous) can cause vascular inflammation within areas of diffusely inflamed parenchyma and must be differentiated from GPA. The presence of vasculitis in an area of otherwise uninvolved lung tissue ensures that the vascular inflammation is not just a consequence of another inflammatory process [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/5\">",
"     5",
"    </a>",
"    ]. However, this finding is infrequent and the diagnosis of GPA does not require it. A separate finding that favors GPA over infection is necrosis of the vascular media, which is rarely noted when vascular inflammation is caused by infection. Negative special stains and cultures are also evidence against an infectious etiology.",
"   </p>",
"   <p>",
"    The granulomatous inflammation of GPA is characterized by palisading histiocytes that are oriented with their long axis perpendicular to the necrotic center [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/5\">",
"     5",
"    </a>",
"    ]. A few noncaseating granulomas may be present, but are not prominent. In general, the inflammatory changes associated with GPA are angiocentric, although a rare bronchocentric variant has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/16\">",
"     16",
"    </a>",
"    ]. The infiltrating inflammatory cells include neutrophils, lymphocytes, multinucleated giant cells, and eosinophils, but eosinophils are generally not abundant. However, eosinophilic variants of GPA have been described. In a case series of four patients with a clinical syndrome consistent with GPA, lung biopsy findings otherwise consistent with GPA were associated with eosinophil infiltration, but not peripheral eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/17\">",
"     17",
"    </a>",
"    ]. In a separate case report, peripheral blood and pleural eosinophilia were associated with lung biopsy findings of classic GPA without eosinophil infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/18\">",
"     18",
"    </a>",
"    ]. Differentiation of the eosinophilic variants of GPA from Churg-Strauss syndrome was based on clinical and histopathologic correlation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\", section on 'Pathology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27177?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Small areas of organizing pneumonia are often seen in association with small suppurative granulomas, foci of bland necrosis, multinucleated giant cells and microabscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/11\">",
"     11",
"    </a>",
"    ]. Rarely, prominent areas of organizing pneumonia are noted [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link&amp;anchor=H2#H2\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4204106\">",
"    <span class=\"h2\">",
"     Alveolar hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary capillaritis is the key histopathologic finding in GPA presenting with diffuse alveolar hemorrhage (",
"    <a class=\"graphic graphic_picture graphicRef76904 \" href=\"UTD.htm?14/16/14592\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef56943 \" href=\"UTD.htm?18/35/18998\">",
"     picture 2",
"    </a>",
"    ); larger vessels are often uninvolved [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Small punctate neutrophilic aggregates within areas of hemorrhage are a clue to the presence of capillaritis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/5\">",
"     5",
"    </a>",
"    ]. A mixed inflammatory cell infiltrate is typically present within the interstitium and airspaces, as well as a small vessel leukocytoclastic vasculitis (ie, presence of degenerating neutrophils with formation of nuclear dust in the vessel wall) (",
"    <a class=\"graphic graphic_picture graphicRef66296 \" href=\"UTD.htm?22/37/23126\">",
"     picture 3",
"    </a>",
"    ). Foamy macrophages and giant cells may be present, but granulomatous inflammation is usually minimal or absent.",
"   </p>",
"   <p>",
"    Pulmonary capillaritis due to GPA is differentiated from that due to systemic lupus erythematosus (SLE) or anti-GBM antibody (Goodpasture&rsquo;s) disease by immunostaining. Granular immune complex deposition is characteristic of SLE and linear IgG deposition along the capillary basement membrane is virtually diagnostic of anti-GBM antibody disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link&amp;anchor=H19#H19\">",
"     \"The diffuse alveolar hemorrhage syndromes\", section on 'Biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=see_link\">",
"     \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemosiderin-laden macrophages, identified by Prussian blue staining that reveals large clumps of hemosiderin, appear in alveoli approximately 48 hours after the onset of hemorrhage are typically noted in the alveoli [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/5\">",
"     5",
"    </a>",
"    ]. The large clumps of hemosiderin differentiate these macrophages from smoker&rsquo;s macrophages, which have a finely stippled pattern of iron deposition in the cytoplasm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link&amp;anchor=H16#H16\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\", section on 'Hemorrhagic BAL'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with granulomatosis with polyangiitis (GPA) (either classic or limited) have either upper airway or pulmonary involvement, and the majority of patients have both. Nonspecific complaints of fever, anorexia, weight loss, and malaise are often present [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/22\">",
"     22",
"    </a>",
"    ]. The clinical manifestations of GPA outside the respiratory tract are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H11698538#H11698538\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nasal, sinus, and ear disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presenting symptoms and signs of GPA related to the nares, sinuses, and ears include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/1,23-27\">",
"     1,23-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nasal crusting",
"     </li>",
"     <li>",
"      Sinus pain",
"     </li>",
"     <li>",
"      Chronic rhinosinusitis",
"     </li>",
"     <li>",
"      Nasal obstruction",
"     </li>",
"     <li>",
"      Smell disturbances",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Purulent/bloody",
"      </span>",
"      nasal discharge",
"     </li>",
"     <li>",
"      Excessive tearing (ie, epiphora)",
"     </li>",
"     <li>",
"      Formation of sinus mucoceles (benign, epithelium-lined cysts filled with mucus)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients often present with symptoms of nasal congestion and purulent nasal discharge suggestive of a sinus infection that has failed to resolve with appropriate antibiotic therapy. Chronic rhinosinus involvement with GPA can lead to nasal septal perforation, saddle nose deformity, serous otitis, and hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/10,23\">",
"     10,23",
"    </a>",
"    ]. Adjacent structures may also be involved (eg, orbital pseudotumor with proptosis and vision impairment, oral ulcers) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nasal, sinus, and ear involvement may be present without other disease manifestations for weeks to months before progressing to more generalized, &ldquo;vasculitic&rdquo; disease. When disease is &ldquo;limited&rdquo;, constitutional symptoms are usually minimal or absent.",
"   </p>",
"   <p>",
"    Unlike Churg-Strauss syndrome (also known as allergic granulomatosis and angiitis), which is also characterized by chronic rhinosinusitis, nasal polyposis is not seen in GPA. In addition, the sinonasal disease associated with Churg-Strauss syndrome is less likely to cause septal perforation or other destructive lesions than GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/29\">",
"     29",
"    </a>",
"    ]. The clinical manifestations of chronic rhinosinusitis in general and as related to Churg-Strauss syndrome are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27177?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\", section on 'Upper airway and ear disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H3250712#H3250712\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lower respiratory tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common lower respiratory tract symptoms in GPA are cough, hemoptysis (due to alveolar hemorrhage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tracheobronchial disease), dyspnea, and pleuritic pain. The severity of symptoms and signs varies considerably from asymptomatic (one-third of patients) to acute and fulminant alveolar hemorrhage with respiratory failure. It is unusual for pulmonary symptoms to occur in the absence of upper respiratory tract symptoms or signs. The specific clinical manifestations vary depending on whether the patient has tracheobronchial disease, lung parenchymal nodules, or alveolar hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4203770\">",
"    <span class=\"h3\">",
"     Tracheobronchial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheobronchial involvement with GPA has several manifestations, including tracheal and bronchial stenosis, mass lesions (inflammatory pseudotumors), tracheobronchial malacia, and tracheoesophageal fistulae [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/10,27\">",
"     10,27",
"    </a>",
"    ]. Associated symptoms include dyspnea, stridor, cough, sputum production, and hemoptysis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subglottic stenosis is the most common manifestation of tracheobronchial GPA; reported frequencies vary from 8 to 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/27,30,31\">",
"       27,30,31",
"      </a>",
"      ]. In a referral population, 22 percent of patients with GPA had subglottic stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/30\">",
"       30",
"      </a>",
"      ]. Subglottic stenosis may be the sole manifestation of GPA and may be severe enough to necessitate tracheostomy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/10,32\">",
"       10,32",
"      </a>",
"      ]. Stridor is a sign of severe subglottic obstruction and requires urgent evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis and management of central airway obstruction\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchial ulceration and stenosis are less common than tracheal stenosis and may be asymptomatic or cause dyspnea, hemoptysis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms of postobstructive pneumonia. Bronchial disease is almost always associated with GPA disease elsewhere.",
"     </li>",
"     <li>",
"      Mass lesions in the trachea and bronchi due to GPA can ulcerate leading to hemoptysis or cause airway obstruction leading to dyspnea and postobstructive infections.",
"     </li>",
"     <li>",
"      Uncommonly, bronchial involvement leads to symptoms and signs of bronchiectasis, such as productive cough, hemoptysis, wheezes, or crackles [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/9,10,33\">",
"       9,10,33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link&amp;anchor=H5990869#H5990869\">",
"       \"Clinical manifestations and diagnosis of bronchiectasis in adults\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4204213\">",
"    <span class=\"h3\">",
"     Lung parenchymal nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often, lung parenchymal nodules do not cause symptoms, although patients often have constitutional or upper airway symptoms, as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Alveolar hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse alveolar hemorrhage (DAH) is a prominent and life-threatening pulmonary manifestation of GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/20,21,34-38\">",
"     20,21,34-38",
"    </a>",
"    ]. It is estimated to occur in 5 to 45 percent of patients, and may be the initial finding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/20,39,40\">",
"     20,39,40",
"    </a>",
"    ]. When accompanied by evidence of glomerulonephritis, it is considered a form of the pulmonary-renal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H14577579#H14577579\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Acute glomerulonephritis and pulmonary hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with alveolar hemorrhage due to GPA typically present with the rapid onset of dyspnea and may also have cough, hemoptysis, anemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoxemia. Untreated, they may progress rapidly to respiratory failure. Associated constitutional symptoms and evidence of skin, neurologic, and renal involvement are common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H11698538#H11698538\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90822002\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and diagnosis of patients with suspected upper or lower respiratory tract involvement with granulomatosis with polyangiitis (GPA) requires a combination of clinical assessment, serologic testing, pulmonary function testing, sinus and chest imaging, bronchoscopy, and tissue biopsy. The diagnosis of GPA is established when serologic and histopathologic evidence of vasculitis and granulomatous inflammation are present in a patient with a compatible clinical presentation. The criteria for the diagnosis of GPA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H11698510#H11698510\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Classification and diagnostic criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H11701485#H11701485\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The order of testing and speed with which it is performed depends in part on the pattern of symptoms and acuity of illness. However, it is important to establish a diagnosis of ANCA-associated vasculitis promptly, as an early diagnosis allows the initiation of therapy that may be life-saving and organ sparing. The results of initial testing, presence of extra-respiratory or co-morbid disease, and local expertise also influence the choice and order of procedures. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If upper respiratory tract disease (eg, nasal obstruction, sinus opacification, crusting, bloody nasal discharge) is prominent and the patient does not have constitutional symptoms, the initial diagnostic evaluation usually includes testing for antineutrophil cytoplasmic antibodies (ANCA) and a sinus computed tomography (CT) scan (if not already performed). A positive ANCA test result is followed by additional laboratory tests (eg, complete blood count with differential, urinalysis, creatinine) and a chest radiograph. If sinus disease is extensive, biopsy of involved nasal or sinus tissue usually follows, but is often nondiagnostic. Further evaluation is aimed at obtaining histopathologic confirmation at another site, such as the skin, kidney, or lungs depending on the results of careful skin examination, laboratory testing, and chest imaging.",
"     </li>",
"     <li>",
"      For patients who present with pulmonary nodules, a positive ANCA test result, and renal insufficiency, but no cutaneous manifestations, the choice between a lung or kidney biopsy is often debated. When pulmonary nodules are peripheral, we typically proceed with a video-assisted thoracoscopic lung biopsy. On the other hand, a patient with progressive renal insufficiency may require a kidney biopsy to fully characterize their kidney disease and guide treatment. If the kidney biopsy shows pauci-immune glomerulonephritis, a lung biopsy may not be necessary. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Tissue biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the patient presents with dyspnea and diffuse radiographic opacities, an expedited evaluation is necessary with routine laboratory tests, a chest CT scan and testing for ANCA and anti-glomerular basement membrane antibodies. The serology results may not be immediately available. Urgent bronchoscopy with a careful airway survey (to exclude ulcerations, stenosis, or mass) and bronchoalveolar lavage in a radiographically involved area are usually performed to assess for alveolar hemorrhage, infection, or malignancy. In general, biopsy confirmation of GPA is highly desirable, but individual patients may be deemed to be poor surgical candidates for lung biopsy and a renal biopsy or empiric therapy may be a better choice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929557\">",
"    <span class=\"h3\">",
"     Routine laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing, other than the antineutrophil cytoplasmic antibody (ANCA), is generally nonspecific in granulomatosis with polyangiitis (GPA). Nonetheless, a complete blood count with differential, plasma creatinine, and urinalysis are obtained in virtually all patients with suspected GPA. For patients with respiratory insufficiency and diffuse radiographic opacities, we also obtain liver and muscle enzymes, antiglomerular basement membrane (anti-GBM) antibodies, antinuclear antibodies (ANA), cryoglobulins, hepatitis serology, HIV screen, and blood cultures to assess potential GPA involvement of other organs and to exclude other processes in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H24#H24\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with nasal ulcerations or a saddle nose deformity, we often screen for cocaine. The saddle nose deformity of syphilis is congenital and thus serologic testing for syphilis is not necessary in patients with acquired saddle nose deformity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link&amp;anchor=H28#H28\">",
"     \"Cocaine abuse and dependence in adults\", section on 'Screening and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common hematologic abnormalities in GPA include a normochromic, normocytic anemia, leukocytosis, thrombocytosis",
"    <span class=\"nowrap\">",
"     (&gt;400,000/mm3),",
"    </span>",
"    and marked elevation of the erythrocyte sedimentation rate (&gt;100",
"    <span class=\"nowrap\">",
"     mm/hour",
"    </span>",
"    by Westergren method) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/1\">",
"     1",
"    </a>",
"    ]. Peripheral eosinophilia is uncommon in GPA and would make Churg-Strauss syndrome more likely, although not entirely excluding GPA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27177?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\", section on 'Eosinophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The plasma creatinine and urinalysis are normal in limited GPA. In contrast, patients with classic GPA typically show a variable elevation in plasma creatinine concentration, mild to moderate proteinuria, and an active urine sediment with red cells, white cells, and red cell and other cellular casts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H11698559#H11698559\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Renal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Antineutrophil cytoplasmic antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An indirect immunofluorescent assay for antineutrophil cytoplasmic antibodies (ANCA) is performed in any adult patient who presents with symptoms or signs suggestive of a vasculitis. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical features'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H20#H20\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Clinical features suggestive of vasculitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Granulomatosis with polyangiitis (Wegener's)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More than 90 percent of patients with active granulomatosis with polyangiitis (GPA) and both lung and kidney involvement have ANCAs in the serum. In some circumstances (eg, nondiagnostic biopsy findings), a positive ANCA may provide the only clue to the correct diagnosis. However, in limited forms of GPA, ANCA testing may be negative. Most patients with GPA have C-ANCA, characterized by diffuse cytoplasmic staining and autoantibodies directed against serine proteinase 3 (PR3); a minority have P-ANCA with a perinuclear staining pattern and autoantibodies directed against myeloperoxidase (MPO). P-ANCA are also found in microscopic polyarteritis, pauci-immune glomerulonephritis, Churg-Strauss syndrome, and the drug-associated polyangiitides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Confirmation of the presence of autoantibodies to PR3 or MPO by the specific enzyme-linked immunoassays leads to substantially higher specificity and positive predictive values than the indirect immunofluorescence assay. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Enzyme-linked immunoassays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function tests (PFTs), including flow volume loops, are obtained in patients with symptoms or signs of airway or lung involvement in granulomatosis with polyangiitis (GPA) to assess the presence of airway involvement and the severity of lung function impairment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data regarding PFT results in GPA are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/1,42\">",
"     1,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The most frequent abnormality is airflow obstruction",
"     </li>",
"     <li>",
"      Reduced lung volumes and diffusing capacity for carbon monoxide (DLCO) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Airflow obstruction may be a harbinger of tracheal obstruction or lobar collapse",
"     </li>",
"     <li>",
"      Reduced lung volumes are found when diffuse interstitial involvement is present",
"     </li>",
"     <li>",
"      The DLCO may be markedly increased in the presence of active alveolar hemorrhage, although these patients are often too dyspneic to perform PFTs",
"     </li>",
"     <li>",
"      Lung function frequently improves following treatment, although the diffusing capacity may not return to normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Flow volume loop tracings may show flattening of the expiratory loop in patients with subglottic or tracheal stenosis when the area of narrowing is still pliable or flattening of both inspiratory and expiratory loops when the lesion is tightly stenotic (",
"    <a class=\"graphic graphic_figure graphicRef76811 \" href=\"UTD.htm?34/31/35325\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link&amp;anchor=H3#H3\">",
"     \"Flow-volume loops\", section on 'Upper airway obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oxygenation is initially assessed with pulse oximetry. A reduced oxygen saturation can be caused by pulmonary hemorrhage, infection, thromboembolism, or fluid overload and requires urgent evaluation with appropriate chest imaging. For patients with impending respiratory failure, arterial blood gas analysis is usually obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90822068\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89945589\">",
"    <span class=\"h3\">",
"     Sinus computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiplanar sinus CT scan is the preferred imaging modality for evaluating chronic rhinosinusitis and suspected rhinosinus involvement by GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In a case series of 28 patients with sinonasal GPA, the most common findings on sinus CT were mucosal thickening in the nasal cavity and paranasal sinuses in 61 and 75 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/43\">",
"     43",
"    </a>",
"    ]. Other findings included bony destruction of the nasal cavity (57 percent), bony destruction of the paranasal sinuses (54 percent), subtotal sinus opacification (25 percent), and bony thickening (sclerosing osteitis) of the paranasal sinuses (18 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H32#H32\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Sinus CT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Chest radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients with GPA have an abnormal chest radiograph, although the appearance is highly variable. The radiographic findings usually include one or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nodules that may cavitate",
"     </li>",
"     <li>",
"      Diffuse hazy opacities, sometimes with an air bronchogram",
"     </li>",
"     <li>",
"      Lobar or segmental atelectasis",
"     </li>",
"     <li>",
"      Pleural opacities",
"     </li>",
"     <li>",
"      Hilar adenopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No clear differences are noted between the chest radiograph manifestations of limited and classic GPA, except that alveolar hemorrhage generally occurs in the setting of systemic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depending on the case series, the most commonly reported chest radiograph findings are nodules (20 to 90 percent) and patchy or diffuse opacities (20 to 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/9,14,39,45\">",
"     9,14,39,45",
"    </a>",
"    ]. Pulmonary nodules may be single or multiple and range in diameter from 1 to 10 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/16\">",
"     16",
"    </a>",
"    ]. The nodules are typically diffuse in distribution and may be cavitary [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/39,46\">",
"     39,46",
"    </a>",
"    ]. Margins may be well-circumscribed or ill-defined.",
"   </p>",
"   <p>",
"    Focal segmental opacities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atelectasis can also occur, often distal to a site of endobronchial involvement (eg, stenosis or a mass) produced by the granulomatous inflammatory process. Other less common findings include pleural effusions, hilar adenopathy, spontaneous pneumothorax (induced by rupture of a subpleural cavitary nodule), and the presence of a fungus ball (eg, aspergilloma) in a cavity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomographic (CT) scans of the chest are obtained in virtually all patients suspected of having GPA based on the chest radiograph or their upper airway, renal, or serologic findings. Chest CT imaging is helpful in disclosing lesions not seen on the plain chest radiograph and in identifying previously unsuspected cavitation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55999 \" href=\"UTD.htm?42/15/43249\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common CT findings in GPA include multiple pulmonary nodules (generally less than 10 in number) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77000 \" href=\"UTD.htm?17/55/18288\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67766 \" href=\"UTD.htm?25/20/25926\">",
"     image 3",
"    </a>",
"    ) and ground glass or consolidative opacities that are patchy or diffuse (due to diffuse pulmonary hemorrhage or active vasculitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/14,41,46\">",
"     14,41,46",
"    </a>",
"    ]. Nodules range in size from a few millimeters to 10 cm. Approximately 30 to 50 percent of nodules are cavitary and 17 percent are diffuse opacities [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/14,22\">",
"     14,22",
"    </a>",
"    ]. Less common findings include a reticular pattern, interlobular septal thickening, honeycombing (in a minority of patients), bronchiectasis, hilar adenopathy, and pleural effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/10,14,41,46\">",
"     10,14,41,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest CT scanning can also identify the presence of other findings that may suggest the diagnosis of vasculitis, including [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/14,46\">",
"     14,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood vessels leading to nodules and cavities (feeding vessels)",
"     </li>",
"     <li>",
"      Small, peripheral, wedge-shaped densities suggesting pulmonary microinfarction",
"     </li>",
"     <li>",
"      Cuffing of the bronchovascular bundle in a lobar segmental and subsegmental distribution, often associated with narrowing of the bronchial lumen",
"     </li>",
"     <li>",
"      Enlarged, irregular, and stellate-shaped peripheral pulmonary arteries (the \"vasculitis\" sign) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Previously unsuspected tracheal or bronchial stenosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80970 \" href=\"UTD.htm?34/31/35327\">",
"       image 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When central airway obstruction due to subglottic or tracheal stenosis is suspected, multidetector computed tomography (MDCT) scanning with two and three dimensional reconstruction can provide thin-section, high-spatial resolution images of the airway [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/48\">",
"     48",
"    </a>",
"    ]. Advantages of MDCT over axial or helical CT imaging include identification of subtle areas of narrowing and a more precise estimate of the craniocaudal extent of stenotic lesions. This technology also allows for noninvasive follow-up of airway lesions during the course of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis and management of central airway obstruction\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929969\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indications for bronchoscopy in patients with suspected GPA are to survey the airway, assess and biopsy endobronchial disease, and to perform bronchoalveolar lavage (BAL). BAL is performed in patients with diffuse parenchymal opacities on chest imaging to identify alveolar hemorrhage, if present, and to obtain samples for microbiologic and cytologic analysis.",
"   </p>",
"   <p>",
"    During the airway survey, careful attention is paid to identify and biopsy areas of friable mucosa, ulceration, masses, or stenosis.",
"   </p>",
"   <p>",
"    When performing BAL to assess for alveolar hemorrhage, three sequential wedged lavages with 50 to 60 mL aliquots are performed in a single area. When alveolar hemorrhage is present, the returned lavage aliquots are progressively more hemorrhagic. Hemosiderin-laden macrophages are often identified on Prussian blue staining of cells from the BAL fluid, although this latter finding does not differentiate alveolar hemorrhage from diffuse alveolar damage. (See",
"    <a class=\"local\" href=\"#H4204106\">",
"     'Alveolar hemorrhage'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link&amp;anchor=H12#H12\">",
"     \"The diffuse alveolar hemorrhage syndromes\", section on 'Bronchoalveolar lavage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link&amp;anchor=H16#H16\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\", section on 'Hemorrhagic BAL'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a mass is seen endobronchially, an endobronchial biopsy is obtained. Histopathology compatible with GPA may be identified, although the size may be too small to make a definitive diagnosis of GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/49\">",
"     49",
"    </a>",
"    ]. Endobronchial biopsy is, however, useful for excluding other diseases such as endobronchial malignancy or sarcoidosis.",
"   </p>",
"   <p>",
"    For patients with multiple pulmonary nodules, bronchoscopy with BAL is useful to evaluate for fungal or mycobacterial infection, but the nodules are usually inaccessible to transbronchial biopsy. The sample size of transbronchial biopsies does not allow for a positive diagnosis of GPA, but may identify an alternative diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175807349\">",
"    <span class=\"h2\">",
"     Lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, tissue confirmation of granulomatosis with polyangiitis (GPA) is desirable due to the potential toxicity of treatment, even among patients with a compatible clinical presentation and positive ANCA serology. The main indication for lung biopsy is the evaluation of single or multiple pulmonary nodules, particularly when extrapulmonary disease is absent or not accessible to biopsy. Even when GPA is strongly suspected (eg, positive ANCA), infection or metastatic disease affecting the lung must be fully excluded prior to initiating immunosuppressive therapy for GPA. (See",
"    <a class=\"local\" href=\"#H175807358\">",
"     'Pathology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Tissue biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Generally, transthoracic needle biopsies, like transbronchoscopic biopsies, are too small for making a definitive diagnosis of GPA, although they may be performed to identify other processes (eg, infection, tumor) in the differential diagnosis. Typically, lung tissue is obtained via a thoracoscopy or thoracotomy. The decision between these techniques depends on the location and size of nodules and radiographic opacities and also local expertise. Smaller, more peripheral nodules and diffuse disease are more amenable to a thoracoscopic approach, while larger more central lesions may require a thoracotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271578039\">",
"    <span class=\"h2\">",
"     Nasal or sinus biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal and sinus biopsies are performed as part of the evaluation and treatment of nasal obstruction due to soft tissue masses and chronic sinusitis, even though the findings are often nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/23,25,26,50\">",
"     23,25,26,50",
"    </a>",
"    ]. As an example, functional endoscopic sinus surgery is often performed for symptoms and signs of recurrent or persistent sinusitis and sinus biopsies are obtained in the course of the procedure. Areas of nasal mucosal ulceration or soft tissue mass are biopsied when present. Biopsies are also indicated when bony erosion or collapse of the nasal bridge are noted [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/23,25,28\">",
"     23,25,28",
"    </a>",
"    ]. Samples are also sent for special stains and culture (eg, fungal, mycobacterial), as well as histopathology (",
"    <a class=\"graphic graphic_table graphicRef63674 \" href=\"UTD.htm?7/8/7309\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H175807366\">",
"     'Chronic rhinosinusitis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link&amp;anchor=H32#H32\">",
"     \"Management of chronic rhinosinusitis\", section on 'Indications for surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90821912\">",
"    <span class=\"h2\">",
"     Testing for tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally perform a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    or blood interferon-gamma release assay (IGRA) as part of the evaluation of patients with suspected GPA. However, a positive result on either of these tests does not necessarily indicate active tuberculosis, nor does a negative test exclude active TB. Patients with latent TB will require anti-tuberculosis treatment when undergoing immunosuppressive therapy for GPA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929710\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of the upper and lower respiratory tract findings associated with granulomatosis with polyangiitis (GPA) is broad, but narrows considerably in the presence of a positive ANCA, particularly when the enzyme-linked immunoassay shows specific antibodies to proteinase 3 (PR3) or myeloperoxidase (MPO). Diseases that require special consideration when evaluating a patient for possible GPA are described in the following sections. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Antineutrophil cytoplasmic antibodies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929781\">",
"    <span class=\"h2\">",
"     Chronic rhinosinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several granulomatous processes can cause a similar presentation to that of GPA sinonasal disease, including infections, Churg-Strauss syndrome, sarcoidosis, extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell nasal lymphoma (previously known as lethal midline granuloma), and others listed in the table (",
"    <a class=\"graphic graphic_table graphicRef63674 \" href=\"UTD.htm?7/8/7309\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Differentiating features include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presence of peripheral blood eosinophilia (usually 5000 to 9000",
"      <span class=\"nowrap\">",
"       eosinophils/microL)",
"      </span>",
"      and nasal polyposis favor CSS, as does prominent eosinophilic infiltration on histopathology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27177?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\", section on 'Laboratory tests'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link&amp;anchor=H11#H11\">",
"       \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\", section on 'Pathology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sarcoidosis is suggested by the presence of lupus pernio or other typical cutaneous manifestations, and also numerous noncaseating granulomas on nasal or sinus biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/20/19786?source=see_link\">",
"       \"Cutaneous manifestations of sarcoidosis\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H175807358\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hearing loss is more common in GPA and CSS than in sarcoidosis.",
"     </li>",
"     <li>",
"      Cocaine-induced midline destructive lesions (CIMDL) can mimic limited GPA and are associated with positive ANCA tests [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. However, in CIMDL the ANCA are less likely to be directed at proteinase 3 or myeloperoxidase and more likely to be directed at human neutrophil elastase [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/53\">",
"       53",
"      </a>",
"      ]. Constitutional symptoms and symptoms suggestive of ear, orbit, or lung involvement are rare in CIMDL and common in GPA. At least partial destruction of the inferior or middle turbinate and septal perforations are common in CIMDL, but uncommon in GPA. Histopathologically, the presence of extravascular granulomas and giant cells rules out CIMDL [",
"      <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Antineutrophil cytoplasmic antibodies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H175807366\">",
"       'Chronic rhinosinusitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell nasal lymphoma is diagnosed by the presence of extensive tissue ulceration and a diffuse and permeative lymphomatous infiltrate with atypical lymphoid cells. The immunophenotype is similar to that of natural killer T cells and Epstein Barr virus genome is virtually always present on in situ hybridization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type\", section on 'Pathologic features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4203939\">",
"    <span class=\"h2\">",
"     Tracheal stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subglottic and lower tracheal lesions need to be differentiated from postintubation stenosis, relapsing polychondritis, tracheopathia osteoplastica, urticarial vasculitis, tracheal amyloidosis, cicatricial pemphigoid, and granulomatous infection. Postintubation stenosis is suggested by a history of intubation and the location of stenosis. Relapsing polychondritis is suggested by coexistent auricular and nasal polychondritis and characteristic findings on tracheal CT. The tracheal changes of relapsing polychondritis usually involve long continuous stretches of the tracheobronchial tree, whereas tracheobronchial lesions of GPA are usually localized and segmental. Tracheopathia osteoplastica also has characteristic CT features. GPA is differentiated from the other processes based on serologic, microbiologic, and histopathologic findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis and management of central airway obstruction\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4856?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnostic evaluation of relapsing polychondritis\", section on 'Computed tomography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25256?source=see_link&amp;anchor=H13#H13\">",
"     \"Radiology of the trachea\", section on 'Relapsing polychondritis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25256?source=see_link&amp;anchor=H14#H14\">",
"     \"Radiology of the trachea\", section on 'Tracheobronchopathia osteochondroplastica'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25256?source=see_link&amp;anchor=H18#H18\">",
"     \"Radiology of the trachea\", section on 'Pseudotumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929788\">",
"    <span class=\"h2\">",
"     Pulmonary nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of multiple pulmonary nodules includes metastatic solid organ malignancy, non-Hodgkin lymphoma, septic emboli, granulomatous infections (eg, Mycobacteria, histoplasmosis, coccidioidomycosis, cryptococcosis, aspergillosis), Paragonimus infection in endemic areas, sarcoidosis, rheumatoid arthritis, lymphomatoid granulomatosis, inflammatory myofibroblastic tumor, silicosis, and coal-worker&rsquo;s pneumoconiosis. Differentiation is based on history of exposures, presence of other features (eg, erosive arthritis, cutaneous lesions), serology, special stains and culture, and histopathology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/34/14888?source=see_link\">",
"     \"Differential diagnosis and evaluation of multiple pulmonary nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929795\">",
"    <span class=\"h2\">",
"     Alveolar hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of alveolar hemorrhage is broad and includes the vasculitides (eg, GPA, cryoglobulinemia, Henoch-Sch&ouml;nlein purpura [IgA vasculitis]), connective tissue diseases (eg, lupus, antiphospholipid antibody syndrome, polymyositis, anti-GBM antibody syndrome), drug-induced lung injury, toxic exposures (eg, trimellitic anhydride), infections, acute respiratory distress syndrome, cardiac dysfunction, and pulmonary infarction (",
"    <a class=\"graphic graphic_table graphicRef52374 \" href=\"UTD.htm?42/62/44013\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link&amp;anchor=H13#H13\">",
"     \"The diffuse alveolar hemorrhage syndromes\", section on 'Clues to a specific etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ) can cause ANCA positivity, alveolar hemorrhage, and glomerulonephritis as part of a drug-induced vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/54\">",
"     54",
"    </a>",
"    ]. As an example, a number of cases of hydralazine-induced alveolar hemorrhage with crescentic glomerulonephritis have been reported in association with pANCA positivity (positive myeloperoxidase) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/14/21738/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Typically, these patients also have positive antinuclear antibodies and antihistone antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of granulomatosis with polyangiitis (Wegener&rsquo;s) and the management of central airway obstruction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis and management of central airway obstruction\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929576\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Classic\" granulomatosis with polyangiitis (Wegener's) is a form of systemic vasculitis (polyangiitis) with necrotizing granulomatous inflammation of the upper and lower respiratory tracts, systemic necrotizing vasculitis, and necrotizing glomerulonephritis. A \"limited\" form, with clinical findings isolated to the upper respiratory tract or the lungs, occurs in approximately one-fourth of cases. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H182265351#H182265351\">",
"       \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'New terminology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Essentially all patients with granulomatosis with polyangiitis (GPA), either classic or limited, have upper airway or pulmonary involvement, and the majority of patients have both. Nonspecific complaints of fever, anorexia, weight loss, and malaise are often present. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common presenting symptoms and signs of GPA affecting to the upper airway include nasal crusting, sinus pain, chronic rhinosinusitis, nasal obstruction, smell disturbances,",
"      <span class=\"nowrap\">",
"       purulent/bloody",
"      </span>",
"      nasal discharge, excessive tearing (ie, epiphora), and sinus mucocele formation. Chronic complications include nasal septal perforation, saddle nose deformity, hearing loss, subglottic stenosis, and tracheal collapse. Other granulomatous diseases that cause nasal and sinus disease are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef63674 \" href=\"UTD.htm?7/8/7309\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nasal, sinus, and ear disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of pulmonary GPA include cough, hemoptysis (due to alveolar hemorrhage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tracheobronchial disease), dyspnea, and less commonly pleuritic pain. The severity of symptoms and signs varies considerably from asymptomatic (one-third of patients) to acute and fulminant alveolar hemorrhage with respiratory failure. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Lower respiratory tract'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antineutrophil cytoplasmic antibody (ANCA) testing is performed in any adult patient who presents with symptoms or signs suggestive of a vasculitis. More than 90 percent of patients with both lung and kidney involvement with active granulomatosis with polyangiitis (GPA) have ANCAs in the serum. In GPA, ANCAs are most commonly directed against serine protease 3 (C-ANCA), but may be directed against myeloperoxidase (P-ANCA). However, the ANCA may be negative in limited GPA. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Antineutrophil cytoplasmic antibodies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Granulomatosis with polyangiitis (Wegener's)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiplanar computed tomography (MDCT) scanning is the preferred imaging modality for characterizing suspected rhinosinus involvement by GPA. Typical findings include mucosal thickening or opacification in the nasal cavity and paranasal sinuses. Bony thickening or destruction of the sinus walls may be noted. (See",
"      <a class=\"local\" href=\"#H89945589\">",
"       'Sinus computed tomography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomographic (CT) scans of the chest are obtained in virtually all patients suspected of having GPA on the basis of their chest radiograph or their upper airway, renal or serologic findings. Common chest CT findings include multiple pulmonary nodules and patchy or diffuse areas of ground glass or consolidative opacities. Less common findings are a reticular pattern, interlobular septal thickening, honeycombing (in a minority of patients), bronchiectasis, pleural effusion, and hilar adenopathy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Computed tomography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of GPA is established when serologic (positive ANCA) and histopathologic evidence of vasculitis with granulomatous inflammation are present in a patient with a compatible clinical presentation and in the absence of medications associated with drug-induced vasculitis. The order of testing and speed with which it is performed depends on the pattern of symptoms and acuity of illness. However, an early diagnosis allows the initiation of therapy that may be life-saving and organ sparing. (See",
"      <a class=\"local\" href=\"#H90822002\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H929710\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tissue confirmation of GPA is desirable, even among patients with a compatible clinical presentation and positive serology. The choice of a biopsy site must be individualized based on the accessibility of specific sites of disease and whether the patient would tolerate the planned procedure. (See",
"      <a class=\"local\" href=\"#H90822002\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of granulomatosis with polyangiitis and the management of central airway obstruction are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"       \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"       \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link\">",
"       \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H3#H3\">",
"       \"Diagnosis and management of central airway obstruction\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/1\">",
"      Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/2\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011; 63:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/3\">",
"      WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin Trials 2002; 23:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/4\">",
"      Sullivan EJ, Hoffman GS. Pulmonary vasculitis. Clin Chest Med 1998; 19:759.",
"     </a>",
"    </li>",
"    <li>",
"     Yousem SA. Wegener's granulomatosis. In: Thurlbeck's Pathology of the Lung, 3rd, Churg AM, Myers JL, Tazelaar HD, Wright JL (Eds), Thieme, New York 2005. p.371.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/6\">",
"      Maguchi S, Fukuda S, Takizawa M. Histological findings in biopsies from patients with cytoplasmic-antineutrophil cytoplasmic antibody (cANCA)-positive Wegener's granulomatosis. Auris Nasus Larynx 2001; 28 Suppl:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/7\">",
"      Tsuzuki K, Fukazawa K, Takebayashi H, et al. Difficulty of diagnosing Wegener's granulomatosis in the head and neck region. Auris Nasus Larynx 2009; 36:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/8\">",
"      Yi ES, Colby TV. Wegener's granulomatosis. Semin Diagn Pathol 2001; 18:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/9\">",
"      Lee KS, Kim TS, Fujimoto K, et al. Thoracic manifestation of Wegener's granulomatosis: CT findings in 30 patients. Eur Radiol 2003; 13:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/10\">",
"      Polychronopoulos VS, Prakash UB, Golbin JM, et al. Airway involvement in Wegener's granulomatosis. Rheum Dis Clin North Am 2007; 33:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/11\">",
"      Travis WD, Hoffman GS, Leavitt RY, et al. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 1991; 15:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/12\">",
"      Daum TE, Specks U, Colby TV, et al. Tracheobronchial involvement in Wegener's granulomatosis. Am J Respir Crit Care Med 1995; 151:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/13\">",
"      Yilmaz A, Damadolu E, Aksoy F, et al. A relapsing case of Wegener's granulomatosis presenting as an endobronchial mass. Tuberk Toraks 2006; 54:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/14\">",
"      Cordier JF, Valeyre D, Guillevin L, et al. Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. Chest 1990; 97:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/15\">",
"      Mark EJ, Flieder DB, Matsubara O. Treated Wegener's granulomatosis: distinctive pathological findings in the lungs of 20 patients and what they tell us about the natural history of the disease. Hum Pathol 1997; 28:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/16\">",
"      Katzenstein AL, Locke WK. Solitary lung lesions in Wegener's granulomatosis. Pathologic findings and clinical significance in 25 cases. Am J Surg Pathol 1995; 19:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/17\">",
"      Yousem SA, Lombard CM. The eosinophilic variant of Wegener's granulomatosis. Hum Pathol 1988; 19:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/18\">",
"      Krupsky M, Landau Z, Lifschitz-Mercer B, Resnitzky P. Wegener's granulomatosis with peripheral eosinophilia. Atypical variant of a classic disease. Chest 1993; 104:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/19\">",
"      Uner AH, Rozum-Slota B, Katzenstein AL. Bronchiolitis obliterans-organizing pneumonia (BOOP)-like variant of Wegener's granulomatosis. A clinicopathologic study of 16 cases. Am J Surg Pathol 1996; 20:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/20\">",
"      Colby, TV. Diffuse pulmonary hemorrhage in Wegener's granulomatosis. Semin Respir Med 1989; 10:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/21\">",
"      Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med 1990; 113:656.",
"     </a>",
"    </li>",
"    <li>",
"     Specks, U. Pulmonary vasculitis. In: Interstitial Lung Disease, 4th, King, TE Jr, Schwarz, MI (Eds), BC Decker, Hamilton, ON 2003. p.615.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/23\">",
"      Cannady SB, Batra PS, Koening C, et al. Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases. Laryngoscope 2009; 119:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/24\">",
"      McDonald TJ, DeRemee RA. Head and neck involvement in Wegener's granulomatosis (WG). Adv Exp Med Biol 1993; 336:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/25\">",
"      Rasmussen N. Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist's perspective. Curr Opin Rheumatol 2001; 13:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/26\">",
"      Gubbels SP, Barkhuizen A, Hwang PH. Head and neck manifestations of Wegener's granulomatosis. Otolaryngol Clin North Am 2003; 36:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/27\">",
"      Taylor SC, Clayburgh DR, Rosenbaum JT, Schindler JS. Progression and management of Wegener's granulomatosis in the head and neck. Laryngoscope 2012; 122:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/28\">",
"      Solans-Laqu&eacute; R, Bosch-Gil J, Canela M, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Lupus 2008; 17:832.",
"     </a>",
"    </li>",
"    <li>",
"     Specks U. Pulmonary vasculitis. In: Interstitial Lung Disease, 5th, Schwartz MI, King TE Jr (Eds), People's Medical Publishing House-USA, Shelton, CT 2011. p.765.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/30\">",
"      Langford CA, Sneller MC, Hallahan CW, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum 1996; 39:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/31\">",
"      Screaton NJ, Sivasothy P, Flower CD, Lockwood CM. Tracheal involvement in Wegener's granulomatosis: evaluation using spiral CT. Clin Radiol 1998; 53:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/32\">",
"      Taylor SC, Clayburgh DR, Rosenbaum JT, Schindler JS. Clinical manifestations and treatment of idiopathic and Wegener granulomatosis-associated subglottic stenosis. JAMA Otolaryngol Head Neck Surg 2013; 139:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/33\">",
"      Woywodt A, Goebel U. Bronchial stenosis and extensive bronchiectasis due to Wegener's granulomatosis. Nephron 2000; 85:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/34\">",
"      Myers JL, Katzenstein AL. Wegener's granulomatosis presenting with massive pulmonary hemorrhage and capillaritis. Am J Surg Pathol 1987; 11:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/35\">",
"      Bosch X, L&oacute;pez-Soto A, Mirapeix E, et al. Antineutrophil cytoplasmic autoantibody-associated alveolar capillaritis in patients presenting with pulmonary hemorrhage. Arch Pathol Lab Med 1994; 118:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/36\">",
"      Yoshimura N, Matsubara O, Tamura A, et al. Wegener's granulomatosis. Associated with diffuse pulmonary hemorrhage. Acta Pathol Jpn 1992; 42:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/37\">",
"      Lenclud C, De Vuyst P, Dupont E, et al. Wegener's granulomatosis presenting as acute respiratory failure with anti-neutrophil-cytoplasm antibodies. Chest 1989; 96:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/38\">",
"      Gaudin PB, Askin FB, Falk RJ, Jennette JC. The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase. Am J Clin Pathol 1995; 104:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/39\">",
"      Pesci A, Pavone L, Buzio C, Manganelli P. Respiratory system involvement in ANCA-associated systemic vasculitides. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 Suppl 1:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/40\">",
"      Schwarz MI, Brown KK. Small vessel vasculitis of the lung. Thorax 2000; 55:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/41\">",
"      Niles JL, B&ouml;ttinger EP, Saurina GR, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med 1996; 156:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/42\">",
"      Rosenberg DM, Weinberger SE, Fulmer JD, et al. Functional correlates of lung involvement in Wegener's granulomatosis. Use of pulmonary function tests in staging and follow-up. Am J Med 1980; 69:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/43\">",
"      Lohrmann C, Uhl M, Warnatz K, et al. Sinonasal computed tomography in patients with Wegener's granulomatosis. J Comput Assist Tomogr 2006; 30:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/44\">",
"      Silvera S, Vignaux O, Legmann P. [Sinonasal and cerebral imaging findings in Wegener's granulomatosis]. Presse Med 2007; 36:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/45\">",
"      Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/46\">",
"      Ananthakrishnan L, Sharma N, Kanne JP. Wegener's granulomatosis in the chest: high-resolution CT findings. AJR Am J Roentgenol 2009; 192:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/47\">",
"      Buschman DL, Waldron JA Jr, King TE Jr. Churg-Strauss pulmonary vasculitis. High-resolution computed tomography scanning and pathologic findings. Am Rev Respir Dis 1990; 142:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/48\">",
"      Lee KS, Boiselle PM. Update on multidetector computed tomography imaging of the airways. J Thorac Imaging 2010; 25:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/49\">",
"      Schnabel A, Holl-Ulrich K, Dalhoff K, et al. Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J 1997; 10:2738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/50\">",
"      Borner U, Landis BN, Banz Y, et al. Diagnostic value of biopsies in identifying cytoplasmic antineutrophil cytoplasmic antibody-negative localized Wegener's granulomatosis presenting primarily with sinonasal disease. Am J Rhinol Allergy 2012; 26:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/51\">",
"      Rachapalli SM, Kiely PD. Cocaine-induced midline destructive lesions mimicking ENT-limited Wegener's granulomatosis. Scand J Rheumatol 2008; 37:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/52\">",
"      Trimarchi M, Gregorini G, Facchetti F, et al. Cocaine-induced midline destructive lesions: clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis. Medicine (Baltimore) 2001; 80:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/53\">",
"      Wiesner O, Russell KA, Lee AS, et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 2004; 50:2954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/54\">",
"      Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol 2008; 20:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/55\">",
"      Dobre M, Wish J, Negrea L. Hydralazine-induced ANCA-positive pauci-immune glomerulonephritis: a case report and literature review. Ren Fail 2009; 31:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/56\">",
"      Kalra A, Yokogawa N, Raja H, et al. Hydralazine-induced pulmonary-renal syndrome: a case report. Am J Ther 2012; 19:e136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/14/21738/abstract/57\">",
"      Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol 2009; 19:338.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4330 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-B86BBD9DD2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21738=[""].join("\n");
var outline_f21_14_21738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H929576\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175807358\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175807366\">",
"      Chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4204045\">",
"      Tracheobronchial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4204099\">",
"      Pulmonary parenchymal nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4204106\">",
"      Alveolar hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nasal, sinus, and ear disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lower respiratory tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4203770\">",
"      - Tracheobronchial disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4204213\">",
"      - Lung parenchymal nodules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Alveolar hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90822002\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H929557\">",
"      - Routine laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90822068\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89945589\">",
"      - Sinus computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Chest radiographs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H929969\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175807349\">",
"      Lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H271578039\">",
"      Nasal or sinus biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90821912\">",
"      Testing for tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H929710\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H929781\">",
"      Chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4203939\">",
"      Tracheal stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H929788\">",
"      Pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H929795\">",
"      Alveolar hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H929576\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4330\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4330|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/15/43249\" title=\"diagnostic image 1\">",
"      Pulmonary hemorrhage in GPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/55/18288\" title=\"diagnostic image 2\">",
"      Tracheal wall involvement in GPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/20/25926\" title=\"diagnostic image 3\">",
"      Pulmonary nodules in GPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/31/35327\" title=\"diagnostic image 4\">",
"      Tracheal stenosis in GPA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4330|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/31/35325\" title=\"figure 1\">",
"      Flow volume loops in airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4330|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/16/14592\" title=\"picture 1\">",
"      Pulmonary capillaritis DAH I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/35/18998\" title=\"picture 2\">",
"      Pulmonary capillaritis DAH II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/37/23126\" title=\"picture 3\">",
"      Leukocytoclastic vasculitis II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4330|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/8/7309\" title=\"table 1\">",
"      Granulomatous diseases nose and sinuses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/62/44013\" title=\"table 2\">",
"      Causes of DAH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27177?source=related_link\">",
"      Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/20/19786?source=related_link\">",
"      Cutaneous manifestations of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4856?source=related_link\">",
"      Diagnostic evaluation of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/34/14888?source=related_link\">",
"      Differential diagnosis and evaluation of multiple pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=related_link\">",
"      Diffusing capacity for carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=related_link\">",
"      Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=related_link\">",
"      Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=related_link\">",
"      Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24824?source=related_link\">",
"      Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25256?source=related_link\">",
"      Radiology of the trachea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=related_link\">",
"      Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_14_21739="Comorbidities and pneumonia";
var content_f21_14_21739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comorbidities associated with delayed resolution of pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Condition",
"      </td>",
"      <td class=\"subtitle1\">",
"       Effects",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic obstructive pulmonary disease",
"      </td>",
"      <td>",
"       Impaired cough and mucociliary clearance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alcoholism",
"      </td>",
"      <td>",
"       Aspiration, malnutrition, impaired neutrophil function",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neurologic disease",
"      </td>",
"      <td>",
"       Aspiration, impaired clearance of secretions and cough",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Heart failure",
"      </td>",
"      <td>",
"       Edema fluid, impaired lymphatic drainage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic kidney disease",
"      </td>",
"      <td>",
"       Hypocomplementemia, impaired macrophage and neutrophil function, reduced humoral immunity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malignancy",
"      </td>",
"      <td>",
"       Impaired immune function, altered colonization, effects of chemotherapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Human immunodeficiency virus",
"      </td>",
"      <td>",
"       Impaired cell-mediated and humoral immunity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diabetes mellitus",
"      </td>",
"      <td>",
"       Impaired neutrophil function and cell-mediated immunity",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21739=[""].join("\n");
var outline_f21_14_21739=null;
var title_f21_14_21740="Spitz tumor grading";
var content_f21_14_21740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Grading system for atypical Spitz tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"90%\">",
"     </colgroup>",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Age (years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0 to 10",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11 to 17",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Diameter, mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0 to 10",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;10",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Subcutaneous involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absent",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Present",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Ulceration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absent",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Present",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Mitotic activity/mm",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0 to 5",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6 to 8",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        &gt;8",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"        *",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         &nbsp;",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *0 to 2 indicates low risk; 3 to 4, intermediate risk; 5 to 11, high risk.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Spatz A, Calonje E, Handfield-Jones S, Barnhill RL. Spitz tumors in children: a grading system for risk stratification. Arch Dermatol 1999; 135:282. Copyright &copy; 1999 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21740=[""].join("\n");
var outline_f21_14_21740=null;
var title_f21_14_21741="Contraindications to fibrinolytic therapy";
var content_f21_14_21741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68784%7ECARD%2F62946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68784%7ECARD%2F62946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Absolute and relative contraindications to the use of thrombolytic therapy in patients with acute ST elevation myocardial infarction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Absolute contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of any intracranial hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of ischemic stroke within the preceding three months, with the important exception of acute ischemic stroke seen within three hours which may be treated with thrombolytic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of a cerebral vascular malformation or a primary or metastatic intracranial malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms or signs suggestive of an aortic dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A bleeding diathesis or active bleeding, with the exception of menses; thrombolytic therapy may increase the risk of moderate bleeding, which is offset by the benefits of thrombolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant closed-head or facial trauma within the preceding three months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Relative contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of chronic, severe, poorly controlled hypertension or uncontrolled hypertension at presentiaton (blood pressure &gt;180 mmHg systolic and/or &gt;110 mmHg diastolic; severe hypertension at presentation can be an absolute contraindication in patients at low risk)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of ischemic stroke more than three months previously",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dementia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any known intracranial disease that is not an absolute contraindication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Traumatic or prolonged (&gt;10 min) cardiopulmonary resuscitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Major surgery within the preceding three weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Internal bleeding within the preceding two to four weeks or an active peptic ulcer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Noncompressible vascular punctures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Current warfarin therapy - the risk of bleeding increases as the INR increases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For streptokinase or anistreplase - a prior exposure (more than five days previously) or allergic reaction to these drugs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * May not be all-inclusive or definitive.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cooperative cardiovascular project risk model for intracranial hemorrhage with thrombolytic therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Risk",
"Factors*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        Age &ge;75 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        Black race",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        Female sex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        Prior history of stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        Systolic blood pressure",
"      &ge;160 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        Weight &le;65 kg for women or &le;80 kg for men",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        INR &gt;4 or PT",
"&gt;24&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        Use of alteplase",
"(versus other thrombolytic agent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Risk score",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Rate of intracranial",
"hemorrhage, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0 or 1",
"       </td>",
"       <td>",
"        0.69",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1.63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2.49",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;5",
"       </td>",
"       <td>",
"        4.11",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Each risk factor is worth 1 point if present, 0 points if absent. Points are added to determine the risk score.",
"     <br>",
"      &bull; INR: international normalized ratio; PT: prothrombin time.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Brass LM, Lichtman JH, Wang Y, et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the cooperative cardiovascular project. Stroke 2000; 31:1802.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21741=[""].join("\n");
var outline_f21_14_21741=null;
var title_f21_14_21742="Revascular in silent ischemia";
var content_f21_14_21742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Revascularization improves outcome in silent ischemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 318px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ACIP study randomized 558 patients with silent ischemia to angina-guided drug therapy, drug therapy guided by elimination of angina and silent ischemia, or revascularization with angioplasty or surgery. After a two year follow-up, the cumulative rate of death, myocardial infarction, or cardiac hospitalization was significantly lower in patient undergoing revascularization compared to those with ischemia or angina-guided drug therapy (23 versus 39 and 42 percent, respectively, p&lt;0.003). There was no difference in outcome between the angina or ischemia-guided groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Davies RF, Goldberg D, Forman S, et al. For the ACIP Investigators. Circulation 1997; 95:2037.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21742=[""].join("\n");
var outline_f21_14_21742=null;
var title_f21_14_21743="Arteriogram in RA stenosis";
var content_f21_14_21743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortogram showing renal artery stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Aortogram shows a focal stenosis of the left renal artery with poststenotic dilatation (arrow). The right renal artery has a normal caliber and is delivering contrast to the right kidney well before the left kidney recieves contrast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_14_21743=[""].join("\n");
var outline_f21_14_21743=null;
